



**Queensland University of Technology**  
Brisbane Australia

This may be the author's version of a work that was submitted/accepted for publication in the following source:

Susaki, Etsuo, Tainaka, Kazuki, Perrin, Dimitri, Yukinaga, Hiroko, Kuno, Akihiro, & Ueda, Hiroki

(2015)

Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging.

*Nature Protocols*, 10(11), pp. 1709-1727.

This file was downloaded from: <https://eprints.qut.edu.au/88909/>

**© Copyright 2015 Nature Publishing Group**

This work is covered by copyright. Unless the document is being made available under a Creative Commons Licence, you must assume that re-use is limited to personal use and that permission from the copyright owner must be obtained for all other uses. If the document is available under a Creative Commons License (or other specified license) then refer to the Licence for details of permitted re-use. It is a condition of access that users recognise and abide by the legal requirements associated with these rights. If you believe that this work infringes copyright please provide details by email to [qut.copyright@qut.edu.au](mailto:qut.copyright@qut.edu.au)

**Notice:** *Please note that this document may not be the Version of Record (i.e. published version) of the work. Author manuscript versions (as Submitted for peer review or as Accepted for publication after peer review) can be identified by an absence of publisher branding and/or typeset appearance. If there is any doubt, please refer to the published source.*

<https://doi.org/10.1038/nprot.2015.085>

1 **Editorial Summary:** This protocol describes how to perform CUBIC (Clear,  
2 Unobstructed Brain/Body Imaging Cocktails and Computational analysis), a simple and  
3 efficient method for organ clearing, imaging by light-sheet microscopy, and quantitative  
4 imaging analysis.

5

6 **Advanced CUBIC protocols for whole-brain and whole-body clearing and imaging**

7

8 **Keywords**

9 CUBIC, Whole-brain and whole-body clearing, Immersion protocol, CB-Perfusion  
10 protocol, Light-sheet fluorescence microscopy (LSFM), Image informatics

11

12 **Authors**

13 Etsuo A. Susaki<sup>1,2,7</sup>, Kazuki Tainaka<sup>1,2,7</sup>, Dimitri Perrin<sup>3,7</sup>, Hiroko Yukinaga<sup>4</sup>, Akihiro  
14 Kuno<sup>1,2,5,6</sup> & Hiroki R. Ueda<sup>1,2,4\*</sup>

15 <sup>1</sup>Department of Systems Pharmacology, The University of Tokyo, Tokyo, Japan.

16 <sup>2</sup>CREST, Japan Science and Technology Agency, Saitama, Japan. <sup>3</sup>Queensland

17 University of Technology (QUT), Brisbane, Australia. <sup>4</sup>Laboratory for Synthetic Biology,

1 RIKEN Quantitative Biology Center, Osaka, Japan. <sup>5</sup>Department of Anatomy and  
2 Embryology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan. <sup>6</sup>Ph.D.  
3 Program in Human Biology, School of Integrative and Global Majors, University of  
4 Tsukuba, Ibaraki, Japan. <sup>7</sup>These authors contributed equally to this work.  
5 Correspondence should be addressed to H.R.U  
6  
7

1 **Abstract/summary**

2 Here we describe a protocol for advanced CUBIC (*C*lear, *U*nobstructed *B*rain/*B*ody  
3 *I*maging *C*ocktails and *C*omputational analysis). The CUBIC protocol enables simple  
4 and efficient organ clearing, rapid imaging by light-sheet microscopy, and quantitative  
5 imaging analysis of multiple samples. The organ/body is cleared by immersion for 1-14  
6 d, with the exact time required dependent on sample type and experimental purposes. A  
7 single set of imaging can be completed in 30-60 min. Image processing and analysis  
8 can take less than 1 d but is dependent on the number of samples in the dataset. The  
9 CUBIC clearing protocol can process multiple samples simultaneously. We previously  
10 used CUBIC to image whole-brain neural activities at single-cell resolution using  
11 Arc-dVenus transgenic (Tg) mice. CUBIC informatics calculated the Venus signal  
12 subtraction, comparing different brains at a whole-organ scale. These protocols provide  
13 a platform for organism-level systems biology by comprehensively detecting cells in a  
14 whole organ or body.

15 (149 words)

16

## 1 INTRODUCTION

2 Since the discovery of the 'cell' as the basic unit of living organisms, people have been  
3 seeking a way to observe all cells inside the body. Comprehensive analysis of cells in  
4 organs and whole organisms is expected to provide information about type, position,  
5 number and activity of cells and cellular networks. Tissue clearing followed by  
6 three-dimensional (3D) imaging is one approach that enables the analysis of multiple  
7 cells simultaneously in organs. Thus development of this and related technologies has  
8 become a recent trend<sup>1,2</sup>.

9

## 10 Development of tissue clearing methods

11 Early tissue clearing methods used organic chemicals (e.g. Benzyl alcohol-methyl  
12 salicylate, BABB, 3DISCO) for this purpose<sup>3-6</sup>. Some of these methods achieved high  
13 transparency within a few days by removing lipids and homogenizing refractive indices  
14 (RI) of the tissue and were shown to be compatible with whole-mount  
15 immunohistochemical analysis<sup>7</sup>. However, concerns about the quenching of fluorescent  
16 proteins and safety issues led to further method development. Very recent publication  
17 addressed this issue, reporting that pH control and temperature during clearing are the  
18 critical points to stabilize fluorescent proteins<sup>8</sup>. Alternative techniques, such as *Scale*<sup>9</sup>,

1 use a hydrophilic chemical urea, and more recently developed tissue clearing methods  
2 use other hydrophilic reagents, including SeeDB<sup>10</sup>, *Clear*<sup>7,11</sup>, or 2,2'-thiodiethanol<sup>12, 13</sup>  
3 and FRUIT<sup>14</sup>. These methods are easy, safe, and fluorescent signals are retained  
4 however have relatively low clearing capability. The introduction of CLARITY enabled  
5 both the fluorescence retention and high transparency by embedding a tissue into  
6 hydrogel polymer and removing most of the lipids by electrophoresis<sup>15</sup>. Possible  
7 drawbacks of CLARITY included its technical difficulty and the limited scalability due to  
8 the need to use a specific device. However, these difficulties have been addressed by  
9 the development of passive clearing protocols that increased the scalability<sup>16, 17</sup>.

10 In this protocol we describe how to perform CUBIC. CUBIC offers a  
11 high-performance and device-free tissue clearing method that preserves fluorescence  
12 based on hydrophilic reagents. It enables reproducible whole-organ and whole-body  
13 clearing. We have used CUBIC for clearing and rapid 3D imaging of whole mouse  
14 brains, a whole marmoset hemisphere, whole mouse organs (e.g. lung and heart) and  
15 whole mouse body. These images were used for image analyses for extracting  
16 biological information<sup>18, 19</sup>.

17

18 **Methods to image cleared tissues**

1 Tissues cleared using the above methods can be imaged in 3D with optical  
2 microscopies. Because some of the above clearing methods render tissues highly  
3 transparent, light-sheet fluorescence microscopy (LSFM) has also been used for  
4 imaging<sup>1,2</sup>. This type of microscopy can collect Z-stack images in a rapid manner and  
5 has been applied to 3D and 4D imaging, such as a time-lapse imaging of developing  
6 embryos or whole-brain calcium dynamics<sup>20-23</sup>. One of the earliest cases of whole  
7 mouse brain imaging was rapid whole-brain imaging of a BABB-cleared brain using a  
8 macrozoom-compatible light-sheet unit (Ultramicroscopy)<sup>4</sup>. More recently, COLM  
9 (CLARITY-optimized light-sheet microscopy) has been used for whole brain-scale  
10 imaging of CLARITY-processed brains<sup>16</sup>. Thus LSFM after an efficient tissue clearing  
11 method facilitates a high-throughput collection of multiple 3D images.

12         Rapid 3D imaging with LSFM can be used following whole-organ and  
13 whole-body clearing by CUBIC. CUBIC also provides processing and analysis of 3D  
14 images for extracting biological information. Therefore, CUBIC presents a platform of  
15 whole-organ/body imaging and image informatics, which enables a wide range of users  
16 to perform experiments targeting cellular and organ layers with multiple samples.

17

18 **Development of CUBIC for efficient and reproducible whole-organ/body clearing**

1 In developing a clearing technique for whole-brain and whole-body imaging we  
2 considered two main criteria, one, efficiency and transparency, and preservation of  
3 fluorescence for a rapid whole-brain/body imaging with LSM, and two, reproducibility  
4 for comparative analysis of multiple samples. Because a clearing method with  
5 hydrophilic reagents had the potential to fulfill these criteria, we started by modifying the  
6 *Scale* recipe<sup>9</sup>. For this purpose, we constructed a new chemical screening method in  
7 which reduction of turbidity of a fixed-brain suspension was measured before and after  
8 mixing with a candidate chemical solution<sup>18</sup>. This screening enables non-biased  
9 discovery of brain clearing chemicals. We screened 40 *Scale*-related chemicals and  
10 found that aminoalcohols, in addition to urea and Triton X-100 in *Scale*, clear tissue with  
11 minimal fluorescent quenching<sup>18</sup>. In the CUBIC clearing protocol, we prepared two  
12 reagents *Scale*CUBIC-1 (reagent-1) and *Scale*CUBIC-2 (reagent-2) which also  
13 minimize light scattering inside the tissue. The first reagent works as a potential lipid  
14 remover. Lipid is thought to be the main light-scattering material inside tissue and its  
15 removal is correlated with the degree of transparency. A fixed brain was treated with the  
16 first reagent for about one week, washed with buffer and then immersed into the second  
17 reagent which has an RI close to ~1.49, similar to that of the *SeeDB* reagent<sup>10</sup>. Moving  
18 from buffer to the second reagent matched RIs between sample and reagent, which



1 further reduced light scattering within the tissue. Thus, a whole mouse brain became  
2 transparent within ~14 d<sup>18</sup>. However, some chemicals seem to have additional or  
3 different roles during the procedure, and thus further studies are needed to elucidate  
4 tissue-clearing mechanisms.

5 In addition to light scattering, light absorption is another challenge in tissue  
6 clearing. We accidentally found that aminoalcohols can remove heme in blood and  
7 tissues<sup>19</sup>, thus CUBIC is able to decolorize tissue. Perfusion of the CUBIC reagent  
8 (CB-Perfusion) was used to efficiently penetrate the mouse body and to accelerate the  
9 clearing and decoloring procedure. The CB-Perfusion protocol enabled not only faster  
10 clearing of dissected tissues, but also whole-body clearing of infant and adult mice<sup>19</sup>.

11 Because of its efficiency and reproducibility, the CUBIC protocol can be applied  
12 to multiple samples in a single experiment, and is scalable from subcellular structures  
13 (e.g. neuronal axons or spines) to marmoset brains to whole animal bodies<sup>18, 19</sup>.  
14 Furthermore, whole-organ counterstaining with a nucleic dye enables precise  
15 positioning of genetically labeled cells in the whole-organ structure, extraction of  
16 specific anatomical structures, and alignment of different samples for comparing signal  
17 intensities<sup>18, 19</sup>.

18

## 1 **CUBIC for whole-organ/body imaging and image informatics**

2 CUBIC-cleared samples can be used in LSM. We use an optimized Ultramicroscope  
3 (LaVision BioTec) for this purpose. In rapid whole-organ imaging, a single, cleared,  
4 whole mouse brain can be imaged within 30-60 min per color and orientation.  
5 Fluorescence wavelength affects the quality of imaging results; in general, red  
6 wavelengths can penetrate deeper in tissue and thus better imaging results are  
7 obtained with red fluorescence than green fluorescence, particularly in deeper regions.  
8 To ensure weaker signals are detected in deeper regions, the sample is imaged in two  
9 orientations; in the case of whole-brain imaging, we took Z-stack images of dorsal side  
10 up (D-V) and ventral side up (V-D) directions.

11 Image visualization software such as Imaris can be used for depicting the  
12 reconstituted 3D image. Imaris implements numerous image analysis functions  
13 including spot counting and surface extraction. We performed extractions of anatomical  
14 structures in the 3D images for comparison of Langerhans islets in normal and diabetic  
15 pancreases, for example<sup>19</sup>. For more complicated analyses, we implemented image  
16 informatics often used in functional magnetic resonance image (fMRI) analysis<sup>18</sup>. First,  
17 structural images via counterstaining were registered to a reference brain to calculate  
18 transformation parameters. Then, the transformation parameters were applied to the

1 corresponding signal images (transgenes etc.) for alignment. These aligned images  
2 could be merged with each other to calculate signal subtraction between samples. This  
3 analysis was performed with open-source software such as Advanced Normalization  
4 Tools (ANTs)<sup>24</sup> and ITK-SNAP<sup>25</sup> but requires advanced informatics and computer  
5 science skills. For the user's convenience, we provide an easier analysis pipeline with  
6 prepared scripts in this manuscript (see below). As an example of the comparative  
7 analysis, we demonstrate 3D image analysis of Arc-dVenus Tg mouse brains with or  
8 without light stimulation and calculate the signal subtraction<sup>18, 26</sup>. The final subtraction  
9 data clearly depicts regions and cells in the whole brain where neurons responded to  
10 the light stimuli. Such direct comparative analysis by using whole-brain fluorescent 3D  
11 images was first reported using CUBIC informatics<sup>18</sup>. CUBIC informatics enables  
12 quantitative identification of stimulus- or timing-dependent neural activities and will help  
13 delineate structural abnormalities in disease samples at the whole-organ and  
14 whole-body scale.

15

## 16 **Overview of CUBIC pipeline**

17 CUBIC provides a platform for a comprehensive analysis of cells in a whole organ or  
18 body. Here we focus on describing: 1) the advanced CUBIC clearing protocols by

1 simple immersion and CB-Perfusion (steps 1-2); 2) whole-brain and -organ imaging with  
2 a LSM (steps 3-6); and 3) CUBIC informatics for preprocessing and comparison of  
3 different brain samples (steps 7-15, see also **Fig. 1**). Although CUBIC is also applicable  
4 to staining with small chemicals or antibodies over days to weeks, as described  
5 previously<sup>18, 19</sup>, we focus here on imaging of fluorescent proteins together with nuclear  
6 counterstaining.

7 **Tissue clearing.** Here we provide three clearing procedures: step 2 option A) simple  
8 immersion protocol for dissected whole organs; step 2 option B) CB-Perfusion and  
9 immersion protocol for faster clearing of whole organs; and step 2 option C)  
10 CB-Perfusion protocol for whole-body clearing. The immersion protocol in our first  
11 CUBIC report<sup>18</sup> has been improved to an advanced version (**Fig. 2**), in which the  
12 clearing speed and efficiency are increased. The CB-Perfusion protocol (**Fig. 3**) is  
13 almost identical to our second CUBIC report<sup>19</sup> but more detail is given in this manuscript.  
14 The clearing performance of CB-perfusion surpasses the immersion protocol,  
15 particularly in heme-rich organs (heart, muscle, kidney, or liver)<sup>19</sup> but tends to cause  
16 decreased signal intensity due to a short fixation time. Incubation period can be varied  
17 and is dependent on the organ and imaging methods to be used (**Fig. 1-3**). Users may  
18 select either of these options and determine the desired final transparency for their

1 experimental purposes. In either option, a paraformaldehyde (PFA) fixation is needed.  
2 Thus animals are transcardially perfused with 4% (wt/vol) PFA and then organs are  
3 dissected for post-fixation (step 1). Alternatively the fixed body can be further perfused  
4 with diluted reagent-1. Samples are subsequently treated with reagent-1 and reagent-2.  
5 Counterstaining is performed during and after reagent-1 treatment<sup>18, 19</sup>. Samples can be  
6 stored at various points in the procedure, indicated in the procedure as PAUSE  
7 POINTS.

8 ***Whole-organ or whole-body imaging.*** We use a commercially available LSMF  
9 (Ultramicroscope, LaVision BioTec) supplied with an optimized macrozoom microscope  
10 (MVX-ZB10, Olympus) and an sCMOS camera (Andor NEO 5.5, 2560 × 2160 pixels). A  
11 customized sample holder is also used for larger brain and body samples and soft  
12 abdominal organs (**Fig. 4a**). A suitable pair of excitation laser and emission filters is also  
13 installed. We typically use 100 mW of 488 nm laser-ET525/50 emission filter for green,  
14 and 50 mW of 588 nm laser-ET650/60 emission filter for red to far-red fluorescence.  
15 The size of the acquired image per pixel is dependent on the zoom of the microscope so  
16 that one pixel is approximately  $\sim 5.2 \times 5.2 \mu\text{m}$  at 2× zoom and one pixel is  $\sim 6.5 \times 6.5 \mu\text{m}$   
17 at 1.6× zoom. These pixel sizes are sufficient for detecting signal from single cells in  
18 regions such as the cerebral cortex, or even from subcellular structures when they were

1 sparsely labeled, as discussed below (**Fig. 4b-f, Supplementary Video 1**). Users can  
2 also use higher magnified zoom values ( $\sim 6.3\times$ ) if finer resolution is needed. Z-step size  
3 is selected according to the thickness of laser sheet. We typically select the thinnest  
4 sheet of the used LSFM and set  $10\ \mu\text{m}$  as the Z-step size. For further image analysis as  
5 below, both signal images (e.g. transgenes) and structural images via whole-organ  
6 counterstaining should be collected. To ensure sharpness of signals throughout the 3D  
7 image, data of the same sample from different directions (D-V and V-D in the case of  
8 whole-brain imaging) are also collected. This is recommended because the ventral  
9 horizontal slices are sharper in V-D images and dorsal horizontal slices are sharper in  
10 D-V images (**Fig. 5**)<sup>18</sup>.

11 If a proper LSFM is not available, widely used confocal or two-photon  
12 microscopies can be also used. Partially cleared samples by one-step immersion in  
13 reagent-1 for 1-3 d are even applicable to deep region imaging with a two-photon  
14 microscopy<sup>18</sup>, because the clearing performance surpasses some of other clearing  
15 methods developed for these imaging purposes<sup>19</sup>. Microscopy vendors have released  
16 objective lenses for deep tissue imaging (e.g. Olympus XLPLN10XSVMP,  $10\times/0.6$ , WD  
17 = 8 mm, ne = 1.33-1.52 and XLSLPLN25XGMP,  $25\times/1.0$ , WD = 8 mm, ne = 1.41-1.52;

1 Zeiss LD Plan-Apochromat 20×1.0 WD = 5.6 mm, ne = 1.43-1.47; Leica HC FLUOTAR  
2 L25×/1.00, WD = 6 mm, ne = 1.457).

3 All raw image data collected in an uncompressed TIFF format (16-bit images for  
4 the LSM, **Fig. 4b**) are typically about ~7 GB in total per brain/color/direction and thus  
5 25-30 GB for a single brain dataset (structural/signal images and D-V/V-D directions).  
6 Therefore, a high-spec PC with a large memory size and good graphic board should be  
7 used for 3D reconstitution (**Fig. 4c-h**). We use a Windows PC with Intel(R) Core(TM)  
8 i7-3970X CPU @ 3.50GHz, 64 GB RAM and NVIDIA GeForce GTX 690 and Imaris  
9 software installed.

10 **CUBIC informatics.** Here we show the step-by-step procedures for data processing  
11 (steps 7-15). For preprocessing of raw data, each TIFF stack (**Fig. 5**, “Collect raw  
12 images”) is first converted to a 3D image in the NIfTI-1 data format (.nii extension)  
13 introduced by the Neuroimaging Informatics Technology Initiative (NIfTI)  
14 (<http://nifti.nih.gov/nifti-1/>). NIfTI-1 files are visualized using software such as  
15 ITK-SNAP<sup>25</sup>. Due to the memory limitations of the current software tools, files need to  
16 be downscaled to 25% by discarding three of every four images of the TIFF Z-stack  
17 series and changing the resolution of these images from 2560 × 2160 to 640 × 540 (**Fig.**  
18 **5**, “Downscaling”). This limitation should be overcome with future development of image

1 informatics tools. The downscaling procedure is done using ImageMagick  
2 (<http://imagemagick.org/>) to create a temporary stack of 16-bit PNG files for each  
3 original TIFF stack. Then, each PNG stack is converted to a NIfTI-1 file using the  
4 Convert3D tool from ITK-SNAP (**Fig. 5**, "Convert to NifTI-1"). In this step, specification  
5 of the correct spacing (given the pixel number of raw image data and downscaling  
6 parameters) and the orientation (which depends on the acquisition direction) is needed.

7 In preparation for merging NIfTI-1 data in the same color channel of the same  
8 brain acquired from opposite directions (D-V and V-D), the files need to be aligned (**Fig.**  
9 **5**, "Align D-V and V-D"). In this step, a pair of NifTI-1 data images, the structural and  
10 signal images, is processed. The structural image is used to calculate the  
11 transformation parameter which is needed to align the D-V image to the V-D image.  
12 This is calculated by the *ANTS* function of the ANTS software. The transformation can  
13 allow deformation (e.g. Symmetric Normalization) or be restricted to affine operations  
14 only. Then, using the *WarpImageMultiTransform* function in ANTS, we apply the  
15 transformation parameters to align both structural and signal images of the D-V image  
16 to the V-D image.

17 Next, we merge the aligned images in order to ensure sharpness throughout the  
18 resulting 3D image (**Fig. 5**, "Combine D-V and V-D"). To do so, we use the Prewitt



1 operator<sup>27</sup> to calculate the “edge content” of the two images (as a proxy for image  
2 sharpness). This is used to define two thresholds,  $n$  and  $m$ , so that slices below  $n$  only  
3 come from the V-D image, slices above  $m$  only come from the D-V image, and slices in  
4 between the two are a linear combination of the two images. We then take the image  
5 pairs and the thresholds, and create the merged NIfTI-1 image. In order to access the  
6 values of individual pixels in the images, we use the *fsl2ascii* and *fslascii2img* functions  
7 of FSL<sup>28</sup>. The steps above produce a pair of D-V + V-D composite NIfTI-1 data for both  
8 structural and signal images.

9 Then, to facilitate analysis across different brain datasets, we align these merged  
10 NIfTI-1 files, which permits subtraction of signal images to be calculated. We show an  
11 example of Arc-dVenus Tg mouse brains with or without light stimuli<sup>18</sup>, which express a  
12 destabilized version of yellow fluorescence protein Venus under control of the *Arc* gene  
13 promoter<sup>26</sup> (**Fig. 6a**). First, the raw data are preprocessed as in **Fig. 5**. Then, the  
14 composite NIfTI-1 images from different samples are aligned (**Fig. 6b**). As before,  
15 images are processed in pairs (structural and signal images), and the process relies on  
16 *ANTS* and *WarpImageMultiTransform*. We first align all brain datasets from the same  
17 experiment to an internal reference (i.e. one of the brain images among the samples of  
18 that experiment). Then, the internal reference is registered to a brain atlas such as the

1 Allen Brain Atlas<sup>29</sup>. These calculations thus provide the aligned 3D images to an atlas  
2 (**Fig. 6c**). Finally, the signal channel images of different brains are compared. To do so,  
3 we normalize these aligned images so that the median intensity inside the brain is the  
4 same across all brains. Then, the *fs/maths* function is used to compare pairs of brains by  
5 subtracting one image from the other (**Fig. 6d**). We provide the set of scripts for all steps  
6 and a brief user guide as **Supplementary Data**, with up-to-date versions also available  
7 on a GitHub repository ([https://github.com/SystemsResearch/CUBIC\\_nprot](https://github.com/SystemsResearch/CUBIC_nprot)). On our  
8 website (<http://cubic.riken.jp>), we also share example raw tiff data of Arc-dVenus Tg  
9 mice shown in **Fig. 6** and NIfTI-1-converted Allen Brain Atlas data.

10 ***Limitations of the current version of CUBIC.*** CUBIC was developed and optimized  
11 for whole-organ and whole-body imaging and informatics analysis developed to enable  
12 a comprehensive pipeline. Thus, there are several important advantages to CUBIC  
13 compared to other clearing methods. The first is the active tissue decoloring ability. This  
14 is mild to proteins, as opposed to the simple flushing or harsh decolorization methods  
15 with peroxidase or acetone used previously<sup>30, 31</sup>. This enables a wide range of  
16 applications for not only the brain but also other organs inside (**Table 1**).

17 Because aqueous reagents are used to clear tissue, and fluorescent signals  
18 are preserved, tissues can be imaged by fluorescence microscopies. To achieve

1 efficient clearing for LSM application, the optimal CUBIC reagent comprises five  
2 chemicals (**Table 2**) and takes days to two weeks to process. However, the procedure  
3 can be modified for the user's purpose: for example if users plan to image by  
4 two-photon microscopy, a one-step immersion in reagent-1 for 1-3 d is sufficient<sup>18</sup>.

5         The actual scalability of CUBIC has not yet been fully investigated. So far, we  
6 tested a hemisphere of infant marmoset, and infant and adult whole mice<sup>18, 19</sup> (**Table 1**).  
7 Clearing of these samples was efficient: for example, in the case of cleared infant  
8 mouse, internal structures of the brain could be imaged directly even through the skull<sup>19</sup>.  
9 However, we have not yet tested adult primate brains (e.g. marmoset), although we  
10 plan to investigate this in future studies. While clearing of larger adult primate brains  
11 might be more difficult, longer incubation times and CB-Perfusion may address this  
12 issue. The PACT/PARS protocol of CLARITY has apparently achieved a similar  
13 scalability and may be considered as an alternative.

14         Whether a tissue clearing method can be combined with particular dyes or  
15 stains is an important consideration when selecting the clearing method. Whole-organ  
16 nuclei staining for anatomical annotation, registration and image analyses has been  
17 achieved using the CUBIC clearing procedure<sup>18, 19</sup>. Although we did not test other  
18 variations of dyes, possible limitations on some labeling methods, particularly lipophilic

1 dye labeling (e.g. Dil and related dyes), may exist given that the CUBIC clearing  
2 reagents massively remove lipids. Dyes or proteins should be fixed by PFA before  
3 clearing. In this sense, fluorescent proteins fused to a membrane protein can be  
4 observed in the cleared tissue while lipophilic dyes such as Dil may not be readily fixed  
5 by PFA due to their chemical structures and thus may be removed during clearing. This  
6 may be a drawback to CUBIC, in which case other clearing methods (e.g. *Clear*<sup>T11</sup>,  
7 SeeDB<sup>10</sup>, FRUIT<sup>14</sup>) should be considered.

8           Structural distortion has been carefully addressed in some of clearing methods,  
9 such as SeeDB, and may need to be considered when clearing tissues with the other  
10 methods. Although we did not observe obvious changes in brain tissue even in the  
11 detailed subcellular structures including the axon and spine<sup>18</sup>, such structural distortion  
12 may happen given that CUBIC reagents remove a large proportion of the lipids and  
13 cause transient swelling during the procedure. In addition, CUBIC has not yet been  
14 optimized to fully clear bone and melanin pigments (**Table 1**). However, this issue  
15 remains unaddressed by other clearing methods also, so we are unable to suggest a  
16 suitable alternative in this scenario. Thus this issue needs further investigation in future  
17 studies.

1           As discussed earlier, imaging resolution is a point to be considered as well. We  
2   have detected and counted signals from a single cell, and in this manuscript we  
3   therefore define this as providing 'single-cell resolution'. This criterion is roughly  
4   evaluated by using spot analysis of Imaris software in the dataset in **Fig. 4**  
5   (hippocampal cells of Thy1-YFP-H Tg) (**Supplementary Video 1**). In our opinion the  
6   criterion is overall supported by the calculated optical resolution. According to the  
7   vender's specifications, the optical resolution of microscopy that we use in this  
8   manuscript has 4.2  $\mu\text{m}$  and 3.7  $\mu\text{m}$  in X-Y images with 1.6 $\times$  and 2 $\times$  zoom, respectively.  
9   The thickness of light sheet is under 10  $\mu\text{m}$  at the thinnest region, smaller than the  
10   typical step size (10  $\mu\text{m}$ ). In a typical nuclei-stained image, a 2.5  $\mu\text{m}$  in half diameter  
11   sphere of a stained nuclei is detected as 2.5 + 3.7  $\mu\text{m}$  in half diameter (actual half  
12   diameter + optical blurring of lens according to the definition of Rayleigh criterion) when  
13   2 $\times$  zoom (5.2  $\mu\text{m}$   $\times$  5.2  $\mu\text{m}$  per pixel) is used. To distinguish two neighboring cells, two  
14   parameters need to be considered: Exclusion volume (EV), the average voxel volume  
15   per cell calculated from cell density; and s, the voxel volume of nuclei acquired by  
16   camera (considered both cell/nuclei diameter and optical blurring). Each nucleus is  
17   detectable and separable if EV is sufficiently larger than s. By our calculations,  $s = 3 \times 3$   
18    $\times 2$  voxels (= 15.6  $\times$  15.6  $\times$  20  $\mu\text{m} = 4867.2 \mu\text{m}^3$ , enough to include a sphere with 2.5 +

1 3.7  $\mu\text{m}$  in its half diameter). EV of mouse cerebral cortex neuron is  $11000 \mu\text{m}^3/\text{cell}^{32} =$   
2  $(22.2 \mu\text{m})^3 = 5 \times 5 \times 3$  voxels, which is sufficiently larger than the voxel volume used in  
3 this study, whereas EV of mouse hippocampal CA1 is  $3900 \mu\text{m}^3/\text{cell}^{33} = (15.7 \mu\text{m})^3 = 3$   
4  $\times 3 \times 2$  to  $4 \times 4 \times 2$  voxels which is at the limit of resolution in the examples of current  
5 manuscript. Thus, the acquired image at its best has 'single-cell resolution' in the cortex  
6 and regions with similar cell density, while the voxel size is not sufficient for 'single-cell  
7 resolution' in denser regions such as the hippocampus or cerebellar granule layer.  
8 Further considerations are that the thinnest area of the sheet is limited and does not  
9 cover the entire imaged field. Also, the analysis software used in this manuscript does  
10 not support large image data and collected data must be downsampled. While CUBIC has  
11 the potential to detect all signals with single-cell resolution, these issues will need to be  
12 further addressed in future studies.

13

1   **MATERIALS**

2   **REAGENTS**

3   **Animal samples used for imaging**

4   • Animals expressing fluorescent proteins can be used. Strong expression of a bright  
5   fluorescent protein gives the best imaging results. A bright red fluorescent protein  
6   such as mKate2 is best. So far, we have confirmed good imaging performance with  
7   Thy1-YFP-H Tg (The Jackson Laboratory), R26-H2B-EGFP KI (RIKEN CDB),  
8   R26-H2B-mCherry KI (RIKEN CDB), R26-CAG-nuc-3×mKate2 KI (RIKEN CDB &  
9   QBiC), β-actin-CAG-nuc-3×mKate2 KI (RIKEN CDB & QBiC), CAG-EGFP Tg (Japan  
10   SLC, Inc.), and Arc-dVenus Tg (Gifu University). We also usually use C57BL/6 (CLEA  
11   Japan, Inc.) to prepare cleared organs and bodies. **! CAUTION** Animals experiments  
12   must be performed in accordance with governmental and institutional regulations  
13   regarding the use of animals for research purposes. All animal experiments and  
14   housing conditions in this manuscript were approved by the Animal Care and Use  
15   Committee of the RIKEN Kobe Institute, The University of Tokyo and the Gifu  
16   University, and all of the animals were cared for and treated humanely in accordance  
17   with the Institutional Guidelines for Experiments using animals.

18   **Fixative, perfusion and storage reagents**

- 1 • PBS tablets (Takara, cat. no. T9181)
- 2 • Heparin sodium (Mochida Pharmaceutical, 10000 U/10 mL)
- 3 • PFA (Nacalai Tesque, cat. no. 02890-45) ! **CAUTION** PFA is toxic. Perform all
- 4 procedures in a fume hood.
- 5 • HCl (Nacalai Tesque, cat. no. 18320-15 or 18321-05) ! **CAUTION** HCl is toxic.
- 6 Perform all procedures in a fume hood.
- 7 • NaOH (Nacalai Tesque, cat. no. 31511-05) ! **CAUTION** NaOH is toxic. Perform all
- 8 procedures in a fume hood.
- 9 • Sucrose (Nacalai Tesque, cat. no. 30403-55 or 30404-45)
- 10 • TISSUE TEK O.C.T. compound (Sakura Finetek, cat. no. 4583)
- 11 • 1/2 diluted ScaleCUBIC-1 (1/2 reagent-1). ScaleCUBIC-1 is mixed with an equivalent
- 12 volume of distilled water. ▲ **CRITICAL** ScaleCUBIC-1 should not be diluted with PBS,
- 13 because contamination of salt decreases the clearing performance.
- 14 **Clearing, nuclei-staining and imaging reagents**
- 15 • *N,N,N',N'*-Tetrakis(2-hydroxypropyl)ethylenediamine (Quadrol, Tokyo Chemical
- 16 Industry, cat. no. T0781)
- 17 • 2,2',2"-Nitrilotriethanol (triethanolamine, Wako, cat. no. 145-05605)
- 18 • Urea (Nacalai Tesque, cat. no. 35904-45 or 35907-15)



1 • Polyethylene glycol mono-*p*-isooctylphenyl ether (Triton X-100). ▲CRITICAL In our  
2 first CUBIC paper<sup>18</sup>, we mentioned that the quality of Triton X-100 product seems  
3 critical for preserving fluorescent signals and we recommended a product from  
4 Nacalai Tesque (cat. no. 25987-85). We further checked the same chemical from  
5 Sigma-Aldrich (cat. no. X100, T9284, T8787, T8532) or Tokyo Chemical Industry (cat.  
6 no. P0873), and neither of them caused fluorescent quenching in the final reagent-1  
7 recipe in a short term and thus can be used as substitutes.

8 • Sucrose (Nacalai Tesque, cat. no. 30403-55 or 30404-45)  
9 • Sodium azide (Nacalai Tesque, cat. no. 31208-82) ! CAUTION Sodium azide is  
10 highly toxic.

11 • SYTO 16 (Life Technologies, cat. no. S7578)

12 • Propidium iodide (PI, Life Technologies, cat. no. P21493)

13 • Silicon oil TSF4300 (Momentive, RI = 1.498)

14 • Mineral oil (Sigma-Aldrich, RI = 1.467, cat. no. M8410)

## 15 EQUIPMENT

16 • 5-ml tube (Eppendorf, cat. no. 0030119.401SG)

17 • 15-ml conical tube (Corning, cat. no. 352096 or 188271)

18 • 30-ml conical tube (Sarstedt, cat. no. 60.544)

- 1 • 50-ml conical tube (Corning, cat. no. 352070 or 227261)
- 2 • Peristaltic pump (EYELA, model: MP-2000) (**Fig. 3a**)
- 3 • 23G intravenous injection needle, butterfly type (Terumo, cat. no. SV-23CLK)
- 4 • 26G×1/2" injection needle (Terumo, cat. no. NN-2613S)
- 5 • T shape stopcock (Terumo, cat. no. TS-TL2K)
- 6 • 1 ml, 10 ml and 20 ml disposable syringe (Terumo, cat. no. SS-01T, SS-1010SZ,
- 7 SS-20ESZ)
- 8 • Vacuum desiccator (AS ONE, cat. no. VXS 1-5943-01) with vacuum pump (ULVAC,
- 9 model: DA-15D) (**Fig. 2b**)
- 10 • Incubation devices. We use hybridization incubator (TAITEC, model: HB-80, **Fig. 2c**)
- 11 or incubator (EYELA, model: FMS-1000 or MHS-2000) with rotator (TAITEC, model:
- 12 RT-5)
- 13 • Shaker (TAITEC, model: Wave-PR or MixerXR-36, **Fig. 2d**)
- 14 • Magnetic stirrer for preparing highly viscous reagent (ASH, model: AMG-S, or IKEDA
- 15 Scientific, model: IS-20PC)
- 16 • Hot stirrer for preparing highly viscous reagent (IKA, model: C-MAG HS10, or
- 17 Advantec, model: SRS710HA)
- 18 • pH meter (HORIBA scientific, model: LAQUA twin)

1 • Positive displacement pipettor (Gilson, model: Microman M-1000). ▲CRITICAL We  
2 highly recommend this pipettor to measure the weight of the viscous materials such  
3 as Triton X-100 and aminoalcohols.

4 • Microwave

5 • Fume hood

## 6 **Imaging microscopy for whole mouse organs**

7 • Light-sheet illumination device with a macrozoom microscope<sup>4, 18</sup>

8 In this study, we used Ultramicroscope from LaVision BioTec and MVX-ZB10 from

9 Olympus, equipped with

10 • Olympus MVPLAPO0.63X lens (NA = 0.15, working distance = 87 mm)

11 • Imaging reservoir (100% quartz) (LaVision BioTec)

12 • Sample holder (LaVision BioTec or customized) (**Fig. 4a**)

13 • Green fluorescent signal filter (Chroma ET525/50)

14 • Red fluorescent signal filter (Chroma ET650/60)

15 • Coherent sapphire laser 488LP-100

16 • Coherent sapphire laser 588LP-50

17 • Andor sCMOS CCD camera Neo 5.5. The camera and the MVX microscope are

18 connected to a camera adaptor (Olympus MVX-TV1X), tube lens (Olympus

- 1 MVX-TLU), and the Ultramicroscope filter wheel unit (LaVision BioTec) with adaptors
- 2 (LaVision BioTec, LV AD MVX-1 and LV AD MVX-2)<sup>18</sup> (**Fig. 4a**).
- 3 • Customized sample holder
- 4 • Glass plate for specimen mounting stage
- 5 **Image analyzing software**
- 6 General image analysis tool
- 7 • ImageJ (freeware from the US National Institutes of Health (NIH))
- 8 Visualization tool
- 9 • Imaris (Bitplane, <http://www.bitplane.com/imaris/imaris>) for 3D reconstitution of TIFF
- 10 image stacks
- 11 • ITK-SNAP (freeware from Paul Yushkevich, Ph.D. at the University of Pennsylvania
- 12 and Guido Gerig, Ph.D. at the University of Utah, DL URL:
- 13 <http://www.itksnap.org/pmwiki/pmwiki.php>) for NIFTI-1 3D images
- 14 Analysis tool
- 15 • Python and a C++ compiler
- 16 • Code provided as **Supplementary Data**
- 17 • ImageMagick (<http://imagemagick.org/>) installed with TIFF support

1 • Convert3D

2 (<http://www.itksnap.org/download/snap/process.php?link=7074&root=nitrc>)

3 • ANTs 1.9-v4 (ANTs, freeware from stnava, DL URL:

4 [http://sourceforge.net/projects/advants/files/ANTS/ANTS\\_Latest/](http://sourceforge.net/projects/advants/files/ANTS/ANTS_Latest/))

5 • FSL (<http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/FslInstallation>)

## 6 REAGENT SETUP

7 **Phosphate buffered saline (PBS)** Prepare according to vendor's manual. When using

8 PBS tablets (Takara, cat. no. T9181), the tablet is dissolved in 1 liter of distilled water.

9 When PBS/0.01% (wt/vol) sodium azide is prepared, directly dissolve 0.1 g of sodium

10 azide in the 1 liter of PBS. This solution can be stored at room temperature (18–25 °C)

11 for several months.

12 **Paraformaldehyde (PFA) solution** To prepare 4% (wt/vol) PFA in PBS, dissolve 40 g

13 of PFA in 1 liter (total) of PBS. Heat the PBS solution (avoid boiling) and add PFA

14 powder and 1/500-1/1000 volume of 1 N NaOH to help dissolving PFA faster. After

15 complete dissolution, adjust the pH to 7.4 using HCl. PFA can be stored at -20°C until

16 use for several months. ▲ **CRITICAL** The pH value of PFA is a critical factor for an

17 efficient clearing with lower autofluorescence. ! **CAUTION** PFA is a very toxic reagent.

1 Avoid inhalation or contact with skin and eyes. Use a draft chamber, proper gloves and  
2 a mask to handle PFA, HCl, and NaOH.

3 **80 wt% Quadrol** Quadrol is a highly viscous liquid and can be used as an 80 wt%  
4 working solution. In this case, add 125 g of distilled water to a 500 g of Quadrol reagent  
5 bottle and stir for at least 30 min. Store the solution at room temperature for up to one  
6 month. ▲ **CRITICAL** Quadrol is highly viscous and we use wt% rather than % (wt/vol)  
7 or % (vol/vol) for convenience.

8 **ScaleCUBIC-1 (Reagent-1)** Reagent-1 is a mixture of urea (25 wt% final concentration),  
9 Quadrol (25 wt% final concentration), Triton X-100 (15 wt% final concentration) and  
10 distilled water. For example to prepare 500 g of reagent-1 solution, mix 125 g of urea,  
11 156 g of 80 wt% Quadrol in 144 g of distilled water until complete dissolution at room  
12 temperature (or with heating if needed) and further add 75 g of Triton X-100. Finally,  
13 degas the reagent with a vacuum desiccator (~0.1 MPa, ~30 min) (**Fig. 2b**). The  
14 reagent can be stored at room temperature for up to one month. Prepare 1/2 reagent-1  
15 by mixing 1:1 of reagent-1 and distilled water. ▲ **CRITICAL** Quadrol and Triton X-100  
16 are viscous and therefore we use wt% rather than % (wt/vol) or % (vol/vol) for  
17 convenience. Reagent-1 should not be prepared with PBS, because contamination of  
18 salt decreases the clearing performance. We usually use the stocked solution but longer

1 storage may cause quenching of fluorescent signals. Avoid excess heating during  
2 preparation

### 3 ? TROUBLESHOOTING

4 **ScaleCUBIC-2 (Reagent-2)** Reagent-2 is a mixture of urea (25 wt% final concentration),  
5 sucrose (50 wt% final concentration), triethanolamine (10 wt% final concentration) and  
6 distilled water. To prepare 50 g of reagent-2 solution, dissolve 12.5 g of urea and 25 g of  
7 sucrose in 7.5 g of distilled water with microwave and hot stirrer (**Fig. 2a**). After  
8 complete dissolution (typically it takes 10-15 min), cool the mixture at room temperature,  
9 add 5 g of triethanolamine, and stir further. The 0.1% (vol/vol) of Triton X-100 included  
10 in the original recipe<sup>18</sup> is not necessary. Finally, degas the reagent with a vacuum  
11 desiccator (~0.1 MPa, ~30 min) (**Fig. 2b**). Prepare 1/2 reagent-2 by mixing 1:1 of  
12 reagent-2 and PBS. Reagent-2 can be stored at room temperature for up to two weeks.

13 ▲ **CRITICAL** Reagent-2 becomes highly viscous and therefore we use wt% rather  
14 than % (wt/vol) or % (vol/vol) for convenience. Because water evaporation will make it  
15 difficult for highly concentrated chemicals to dissolve, the weight should be monitored  
16 for the addition of evaporated water after completely dissolving urea and sucrose. Avoid  
17 boiling during the preparation. ▲ **CRITICAL** Reagent-2 should not be prepared with  
18 PBS, because contamination of salt decreases the clearing performance. We use PBS

1 only in preparing 1/2 reagent-2/PBS, because tissues after reagent-1 treatment tend to  
2 be easily swollen in 1/2 reagent-2/water, which might cause distortion of overall  
3 structure, and because the gradual exchange from PBS through 1/2 reagent-2/PBS to  
4 salt-free reagent-2 does not affect the final transparency. Before clearing, 1/2  
5 reagent-1/water is not a problem. ▲ **CRITICAL** Make sure that there is no precipitation  
6 in the reagent-2 solution stock before use. The precipitation in the stock can be  
7 dissolved again by mild heating with microwave. Insufficient degassing may cause  
8 bubbles around and inside the tissue during reagent-2 treatment. ! **CAUTION** The acrid  
9 ammonia smell in these reagents indicates degradation of urea. Generation of ammonia  
10 itself is not apparently a problem because the reagents are buffered with aminoalcohol  
11 in alkaline pH range (~pH 11)<sup>19</sup>. We recommend users to avoid excess heating during  
12 preparation. If users experience the smell during clearing, change to the fresh media.

### 13 ? TROUBLESHOOTING

14 **Immersion oil mix** Mix 1:1 of TSF4300 and mineral oil completely with stirrer and  
15 degas with a vacuum desiccator (~0.1 MPa, ~30 min) (**Fig. 2b**) before use. The oil mix  
16 can be repeatedly used for imaging by filtering contaminants (clearing reagents etc.). Its  
17 RI is 1.48-1.49, a comparable RI of reagent-2. The oil can be wiped out with 70% EtOH.



1   ▲**CRITICAL** The mix ratio can be optionally changed because the best RI matching  
2   may be different between organs.

### 3   **EQUIPMENT SETUP**

4   **Surgical setup for CB-Perfusion protocol** Typical surgical setup for CB-Perfusion is  
5   depicted in **Fig 3a**. In the protocol, the adult mouse is perfused with four solutions:(1)  
6   20-30 ml of cold heparin-PBS, (2) 150 ml of cold 4% (wt/vol) PFA, (3) 20 ml of PBS, (4)  
7   20-30 ml of 1/2 diluted reagent-1. We recommend that PFA is perfused by peristaltic  
8   pump for successful and reproducible surgeries. Thus, we devised a surgical instrument  
9   with a combination of T shape stopcocks, a peristaltic pump connected with silicon tube,  
10  an intravenous injection needle, and a disposable syringe as shown in **Fig 3a. !**

11  **CAUTION** PFA is a very toxic reagent. Avoid inhalation or contact with skin and eyes.  
12  Use a draft chamber, proper gloves and a mask to handle PFA. Great care in handling  
13  the injection needle is needed to avoid accidental needlesticks.

14

1   **PROCEDURE**

2   **Anesthesia ● TIMING 5 min**

3   **1|** At day 0, deeply anesthetize the mice using pentobarbital (~150 mg/kg of body  
4   weight, administer intraperitoneally with 1 ml syringe and 26G×1/2" injection needle).

5   **! CAUTION** Every experiment must follow all government and institutional guidelines for  
6   the use of experimental animals.

7

8   **Transcardial perfusion and tissue clearing ● TIMING 4-14 d**

9   **▲CRITICAL** In this step, we particularly focus on the full clearing protocol for the  
10   purpose of LSM imaging. However, the immersion period and the final transparency of  
11   samples can be varied according to user's experimental purpose.

12   **2|** Start clearing organs by simple immersion protocol (option A) or CB-Perfusion and  
13   immersion protocol (option B) (CB-Perfusion clears better than the immersion protocol,  
14   particularly in heme-rich organs, but tends to cause decreased signal intensity due to  
15   the shorter fixation time). Alternatively start clearing a whole-body by the CB-Perfusion  
16   protocol (option C).

17   **▲CRITICAL STEP** Option A is for a single whole mouse brain (**Fig. 2**) and may need  
18   some modifications when other organs are cleared. Because handling of whole-body

1 samples in the viscous reagent-2 become difficult, particularly due to causing bubbles,  
2 the cleared whole body with option C is kept in reagent-1 but not in reagent-2.

### 3 **(A) Simple immersion protocol for dissected whole brain**

4 (i) Day 0: Perfuse the mice with 10 ml of cold PBS (pH 7.4) containing 10 U/ml of  
5 heparin at ~10 ml/min to remove the blood from the organ as much as possible.  
6 Then, perfuse ~25 ml of cold 4% (wt/vol) PFA (pH 7.4) at ~10 ml/min. Dissect the  
7 brain and postfix in 10 ml of 4% (wt/vol) PFA with shaking at 4°C for 18-24 h.

8 **▲ CRITICAL STEP** Cooling of PBS and 4% (wt/vol) PFA on ice is important for  
9 successful perfusion. Muscle stiffness after perfusion is a good indicator of  
10 successful perfusion. Residual blood in the mouse brain increases  
11 autofluorescence especially in the green-laser excitation. The pH value of PFA is  
12 also critical for efficient clearing and lower autofluorescence. Overfixation causes  
13 both lower clearing efficiency and autofluorescence.

### 14 **? TROUBLESHOOTING**

15 (ii) Day 1: wash the tissue sample with 10 ml of PBS/0.01% (wt/vol) sodium azide for  
16 at least 2 h twice at room temperature to remove the remaining PFA. (**Fig. 2e**,  
17 “Fixed brain” panel)

1       ■ **PAUSE POINT** The fixed organs can be stored. First immerse them in 10 ml of  
2       20-30% (wt/vol) sucrose in PBS per organ with shaking at 4°C for 1-2 d. When  
3       samples sink to the bottom, put them into O.C.T. compound and immediately  
4       transfer to –80°C. To continue the clearing protocol, thaw samples gradually at  
5       room temperature, wash with PBS at least twice, with each wash for 1 h, to remove  
6       sucrose and O.C.T. compound. The sample will now be ready for the next step,  
7       however, we find the clearing efficiency is reduced in samples that have been  
8       stored.

9       (iii) Immerse the sample in 8-10 ml of 1/2 water-diluted reagent-1 with shaking (~60  
10       r.p.m. if using the orbital shaker of a hybridization oven in **Fig. 2c**, ~30 r.p.m. if  
11       using a seesaw shaker in **Fig. 2d**) or rotation (~5 r.p.m.) at 37°C for 3-6 h. We  
12       recommend using a 30-ml of conical tube for clearing a single brain rather than a  
13       15-ml tube in this and further clearing steps (iv-v) because of sample swelling.  
14       Clearing effects can be observed during this step (**Fig. 2e**, “1/2 reagent-1” panel).  
15       Note that a nuclear staining dye, such as SYTO 16 (1-2 µM) and PI (5-10 µg/ml),  
16       can also be added to 1/2 diluted reagent-1 at this step.

17       ▲ **CRITICAL STEP** Inefficient mixing of the reagent and samples during clearing  
18       may affect the final clearing performance. Pretreatment with 1/2 diluted reagent-1

1 gives a more effective final clearing efficiency than direct immersion in reagent-1.  
2 However, this step can be skipped for other purposes such as two-photon imaging  
3 with a partially cleared sample, for example<sup>18</sup>. This direct immersion procedure  
4 gives better clearing results than some other clearing methods<sup>19</sup> and can be used  
5 for two-photon imaging<sup>18</sup> and possibly as part of the sample preparation for  
6 single-photon imaging.

7 (iv) Discard 1/2 diluted reagent-1. Immediately add 8-10 ml of reagent-1 and gently  
8 shake or rotate the sample at 37°C overnight. If desired, the same concentration of  
9 nuclear staining dye used in the previous step should be added to reagent-1.

10 **! CAUTION** Reagent-1 can erase oily pen marks easily. Make sure the tube is  
11 sealed by wrapping parafilm around the lid/top of it. Sample labels should be  
12 written on both the body and lid of the tube to avoid loss of information. An  
13 ammonia smell indicates degradation of urea, and that the reagent should be  
14 replaced by fresh media.

#### 15 **? TROUBLESHOOTING**

16 (v) Day 2: replace 8-10 ml of reagent-1 and continue gentle shaking or rotating at 37°C.  
17 Replace the reagent every two days (day 4 and 6). Also refresh any nuclear

1 staining dye on day 4 and day 6. Typically, the brain will be sufficiently cleared by  
2 day 7-8 (**Fig. 2e**, “Reagent-1” panel).

3 **▲ CRITICAL STEP** If the white matter has not significantly cleared by 8-day  
4 immersion, try further immersion by placing into fresh reagent-1 for an additional  
5 1-2 d.

6 **! CAUTION** Since CUBIC-treated organs soften, we recommend using spoons  
7 instead of forceps for handling them in order to avoid damage.

#### 8 **? TROUBLESHOOTING**

9 (vi) Day 7-10: To stop the clearing procedure, wash the sample with 20 ml of  
10 PBS/0.01% (wt/vol) sodium azide with gentle shaking or rotating at room  
11 temperature for at least 2 h × 3 times. We typically wash the sample for 2 h × 1,  
12 overnight × 1 and 2 h × 1. When a sample is stained with PI, further staining during  
13 this step is needed: thus incubate the washed sample in ~5 ml of PBS/0.01%  
14 (wt/vol) sodium azide containing 5-10 µg/ml of PI for additional 3 d (or more, if  
15 needed) at 37°C with rotation<sup>18</sup>.

16 **▲ CRITICAL STEP** Complete removal of reagent-1 during the washing step is  
17 critical for final clearing efficiency.

1        **■ PAUSE POINT** Organs can be stored. First immerse them in 10 ml of 30%  
2        (wt/vol) sucrose in PBS/0.01% (wt/vol) sodium azide per organ with shaking at  
3        room temperature overnight. When samples sink to the bottom, put them into  
4        O.C.T. compound and immediately store them at  $-80^{\circ}\text{C}$ . Thaw as described in the  
5        PAUSE POINT at step (ii).

6        **! CRITICAL STEP** For cryoprotection at this step, we recommend using 30%  
7        (wt/vol) sucrose in PBS rather than 20% (wt/vol) sucrose solution to avoid any  
8        damage to the sample.

#### 9        **? TROUBLESHOOTING**

10      (vii) Day 8-11: Degas the sample in a limited volume of PBS with a vacuum desiccator  
11      (**Fig. 2b**). To do this, immerse the sample in ~5 ml of 1/2 PBS-diluted reagent-2  
12      and shake it in 5 ml tube for 6 h to 24 h at  $37^{\circ}\text{C}$  or room temperature (**Fig. 2e**, “1/2  
13      reagent-2” panel). Check whether the sample sinks to the bottom (a sign of  
14      complete immersion).

15      **▲ CRITICAL STEP** Degassing of sample prevents air bubbles from remaining in  
16      the ventricle.

1 (viii) Day 8-11: Immerse the sample in ~5 ml of reagent-2 in a 5 ml tube and gently  
2 shake at 37°C overnight. The next day, replace the reagent with fresh reagent and  
3 further incubate for ~24 h (**Fig. 2e**, “Reagent-2” panel).

4 **! CAUTION** Do not rotate the tube to avoid making bubbles. Samples do not sink in  
5 the highly viscous reagent-2 and it is difficult to take images in the reagent. The  
6 reagent-2-treated samples should be immersed in the low-viscous immersion oil  
7 mix at imaging steps. When structural distortion is apparent after reagent-2  
8 treatment at 37°C, try incubation at room temperature for a longer time. Adjustment  
9 of PBS content in 1/2 reagent-2 may also have an effect to mitigate unsuited  
10 shrinkage or swelling.

11 **■ PAUSE POINT** Organs can be left in reagent-2 for up to one week at room  
12 temperature. Further immersion increases the final transparency but also causes  
13 swelling of the sample. After imaging, the sample can be washed with PBS/0.01%  
14 (wt/vol) sodium azide, completely immersed in 30% (wt/vol) sucrose in PBS/0.01%  
15 (wt/vol) sodium azide, and stored in O.C.T. compound at –80°C as described in the  
16 PAUSEPOINT to step (vi).

17 **? TROUBLESHOOTING**

18 **(B) CB-Perfusion and immersion protocol for faster clearing of whole organs**



- 1 (i) Prepare the surgical setup as shown in **Fig. 3a**.
- 2 (ii) Day 0: Perfuse the mice with 20-30 ml of cold PBS (pH 7.4) containing 10 U/ml of  
3 heparin at ~10 ml/min to remove the blood from the tissues as much as possible.
- 4 **▲ CRITICAL STEP** Insufficient removal of blood inside the tissue prolongs the  
5 clearing period and may cause low clearing performance.
- 6 (iii) Perfuse the mice with 150 ml of cold 4% (wt/vol) PFA in PBS (pH 7.4) at ~15 ml/min  
7 using a peristaltic pump.
- 8 **! CAUTION** PFA is a very toxic reagent. Perform all procedures in a fume hood  
9 with a safety glass to avoid inhalation or contact with skin and eyes.
- 10 **▲ CRITICAL STEP** If the signal from a target reporter protein is weak, a prolonged  
11 perfusion period may be more effective, or clearing as described in option A.
- 12 **▲ CRITICAL STEP** Cooling of PBS and 4% (wt/vol) PFA on ice is important for  
13 successful perfusion.
- 14 **? TROUBLESHOOTING**
- 15 (iv) Perfuse the mice with 20 ml of PBS (pH 7.4) at ~10 ml/min to wash out PFA,  
16 followed by perfusion of 20-30 ml of 1/2 diluted reagent-1 at the same injection rate.  
17 Make sure that organs become translucent by the end of the perfusion (**Fig. 3b**).

1 Note that a nuclear staining dye, such as SYTO 16 (1-2  $\mu$ M) and PI (5-10  $\mu$ g/ml),  
2 can also be added to 1/2 diluted reagent-1 at this CB-Perfusion step.

3 **▲CRITICAL STEP** Perfusion efficiency is crucial to the final clearing efficiency.

4 Some organs such as the pancreas and spleen are good indicators to evaluate  
5 perfusion efficiency (**Fig. 3b**).

6 (v) Dissect the organs of interest and immerse these in reagent-1. Several organs can  
7 be processed in a single tube, but the stomach and intestine should be separated  
8 into different tubes. Gastrointestinal content in these organs should be removed as  
9 much as possible in this step. Thus immerse several organs such as heart, lung,  
10 kidney, spleen, pancreas and a piece of liver in 40 ml of reagent-1 or immerse each  
11 small organ such as heart, lung, kidney, spleen, and pancreas in 5 ml of reagent-1.  
12 Incubate the samples with shaking (~60 r.p.m. if using an orbital shaker in a  
13 hybridization oven in **Fig. 2c**, ~30 r.p.m. if using a seesaw shaker in **Fig. 2d**) or  
14 rotation (~5 r.p.m.) at 37°C overnight. Add the same concentration of any nuclear  
15 staining dye used at step (iv) to reagent-1.

16 **▲CRITICAL STEP** Efficient mixing of the reagent and samples during clearing  
17 may affect the final clearing performance. For efficient clearing, the samples of  
18 interest should be immersed in at least 5-fold volume of reagent-1.

1       **! CAUTION** Reagent-1 erases oily pen marks easily. Make sure the tube is sealed  
2       by wrapping parafilm around the lid/top of it. Sample labels should be written on  
3       both body and lid of the tube to avoid loss of information. An ammonia smell  
4       indicates degradation of urea, and in this scenario the reagent should be replaced  
5       with fresh media.

## 6       **? TROUBLESHOOTING**

7       (vi) Day 1: make sure that organs are transparent and the color of the supernatant has  
8       turned olive green. Replace reagent-1 with the same volume of reagent-1 and  
9       continue clearing shaking at 37°C. If appropriate, also refresh the nuclear staining  
10      dye. Replace reagent-1 and any nuclear staining dye again at day 2 and 4. The  
11      total incubation time for the complete clearing depends on the organ: 1-day of  
12      reagent-1 treatment is usually sufficient in the case of pancreas, spleen, and  
13      intestine. However, note that we treated all indicated organs in **Fig. 3c** with  
14      reagent-1 for 5 d.

15      **▲ CRITICAL STEP** Typically, successfully CB-Perfused-organs are turned almost  
16      transparent with the exception of liver and lung by day 1 (**Fig. 3c**). Opacity in the  
17      lung occurs mainly from bubbles. Note that the color change of the supernatant  
18      indicates decolorization of tissues due to heme elution.

## 1        ? TROUBLESHOOTING

2        (vii) Day 2-6: To stop the clearing procedure, wash the samples with same volume of  
3        PBS with gently shaking or rotating at room temperature for 2 h × 3 times. After the  
4        PBS wash, move to the next step immediately.

5        **! CRITICAL STEP** CB-Perfused samples are prone to overshrink in the washing  
6        step. Do not wash the samples in PBS more than 3 times × 2 h.

7        (viii) Immerse the sample in the same volume of 1/2 PBS-diluted glycerol and shake for  
8        6 h to 24 h at room temperature. Check whether the sample sinks to the bottom (a  
9        sign of complete immersion).

10       (ix) Day 3-7: Immerse the samples in the same volume of reagent-2 and gently shake  
11       at 37°C overnight. The next day, replace the reagent with fresh reagent and further  
12       incubate for several days. Typically, an apparent transparency plateau is reached  
13       after 2-3 d of reagent-2 treatment. At day 10, almost all organs should be  
14       transparent as shown in **Fig. 3c**. The gastrointestinal content in stomach and  
15       intestine should be removed as much as possible before the following imaging  
16       step.

17       **! CAUTION** To avoid making bubbles, do not rotate the tube. Samples do not sink  
18       in the highly viscous reagent-2 and it is difficult to take images in the reagent. The

1 reagent-2-treated samples should be immersed in the low-viscous immersion oil  
2 mix at imaging steps. When structural distortion is apparent after reagent-2  
3 treatment at 37°C, try the incubation at room temperature for a longer time. Or, test  
4 the simple immersion protocol (step **(A)**).

## 5 **? TROUBLESHOOTING**

6 **■ PAUSE POINT** Tissues can be left in reagent-2 for up to one week at room  
7 temperature. Further immersion increases the final transparency but also causes  
8 swelling of the sample. After imaging, the sample can be washed with PBS,  
9 completely immersed in 30% (wt/vol) sucrose in PBS, and stored in O.C.T.  
10 compound at –80°C, as in the PAUSE POINT for step **(A)** (vi)

## 11 **(C) CB-Perfusion protocol for whole-body clearing**

12 **▲ CRITICAL** Here, we describe clearing of whole adult mouse body only using  
13 reagent-1. This overcomes the difficulties of handling whole-body samples in the  
14 viscous reagent-2, particularly due to bubble formation. For infant mouse whole-body  
15 imaging, perfusion and immersion of reagent-1 was sufficient (**Table 1**)<sup>19</sup>. Adult  
16 whole-body imaging is not applicable with the microscope setup introduced in this  
17 manuscript due to stage size limitations.

18 (i) (Perform CB-Perfusion as described in **option B**) steps (i)-(iv).

1 (ii) Detach the skin from the body. Carefully remove as much pelage as possible. Make  
2 sure that the body is partially transparent following the CB-Perfusion. Typically,  
3 glands such as pancreas and submaxillary gland are almost transparent (**Fig. 3d**).  
4 Spleen is also as a good indicator of successful perfusion. Immerse the body in 200  
5 ml of reagent-1. Place the container on orbital shaker set at ~60 r.p.m. or seesaw  
6 shaker set at ~30 r.p.m. in the incubator at 37°C overnight. Use the same  
7 concentration of the nuclear staining dye used at step **B** (iv) and add to reagent-1 if  
8 desired.

9 ▲**CRITICAL STEP** Inefficient mixing of the reagent and samples during clearing  
10 may affect the final clearing performance.

11 (iii) Replace the same volume of reagent-1 and continue gentle shaking at 37°C.  
12 Refresh the nuclear staining dye if used also. Replace the reagent (and any nuclear  
13 staining dye) every day in the initial week, and every two or three days in the  
14 second week. Continue the clearing with reagent-1 for at least two weeks. Typically,  
15 major abdominal organs except bones and intestinal content become sufficiently  
16 transparent after two weeks of reagent-1 treatment (**Fig. 3d**).

17 ▲**CRITICAL STEP** An ammonia smell indicates degradation of urea, and the  
18 reagent should be replaced with fresh media in this case.

1       ■ **PAUSE POINT** The whole body can be kept in reagent-1 for up to several  
2       months at room temperature.

3       ? **TROUBLESHOOTING**

4

5       **Imaging of the cleared tissues with the macrozoom LSM** ● **TIMING 1-3**  
6       **h/sample**, timing is dependent on the number of samples, color and direction as well as  
7       required exposure time.

8       ▲ **CRITICAL** To perform a rapid image acquisition of whole organs, a light-sheet  
9       illumination unit combined with a macrozoom microscope is suitable. Here we describe  
10      our setup using Ultramicroscope/MVX-ZB10 (LaVision BioTec/Olympus). A confocal or  
11      a multi-photon microscopy can be also applied but for more limited regions.

12      **3|** Before imaging, wipe reagent-2-treated samples with a kimwipe softly to remove  
13      excess reagent-2 on the surface and then immerse the sample into the oil mix for 10  
14      min to 1 h. This process also helps remove bubbles around the tissue. If bubbles attach  
15      on the surface of the sample, carefully remove them with a needle or a tapered forceps.

16

17      **4|** Set the imaging reservoir filled with the immersion oil mix, and then set the sample  
18      holder. Put a glass slide on the sample holder (**Fig. 4a**).

1

2 **5|** Put the sample on the glass slide (**Fig. 4a**). Acquire a live image with an appropriate  
3 laser/filter pair to adjust focus and the sample position to the center. A whole mouse  
4 brain image can be captured using 1.6× to 2× zoom of the MVX-ZB10.

5 **▲ CRITICAL STEP** To avoid fluorescent quenching, laser power should be weakened  
6 during the adjustment of position and focus.

7

8 **6|** Set the focus position of illumination sheet, Z-range (in the case of whole brain,  
9 typically ~7 mm in total), Z-step size (typically 10 μm per step), laser power (typically  
10 70-100%) and exposure time (typically 50 ms to 1 s for each side). Each plane should  
11 be illuminated from both the right and left sides, and a merged image with max intensity  
12 saved. The exposure times should be adjusted according to the fluorescent signal  
13 intensities of each sample. After all parameters are adjusted, start image acquisition.  
14 When multi-color images are needed, repeat the image acquisition procedure with the  
15 same Z-range and re-adjusted laser power and exposure time. For collecting both D-V  
16 and V-D datasets, manually flip the sample upside down and acquire image again for  
17 this opposite orientation.



1 **▲ CRITICAL STEP** To take images with a high signal-to-noise ratio, it is important to  
2 use bright fluorescent proteins and chemicals. Because ~700 images (~11 MB per  
3 image, total ~7 GB) are acquired per color/direction, each image should be saved to a  
4 secondary storage (e.g. a hard-disc drive) during acquisition. Each stack (one color, one  
5 direction) is saved to a different folder. For further signal comparison steps (step 7-15),  
6 signal and structural images of both D-V and V-D directions are needed. We  
7 recommend a simple naming rule for these folders with four fields separated by an  
8 underscore: information about the experiment (including imaging date), a unique ID for  
9 this brain, information about the imaging direction (“VD” or “DV”) and information about  
10 the channel (“nuclear” for the nuclear counterstaining and “geneExp” for the signal  
11 channel). For instance, 20131118LAdV\_001\_nuclear\_DV. The code provided for the  
12 informatics section assumes that the naming convention is respected. It is also  
13 important to note that white spaces and special characters must be avoided.

#### 14 **? TROUBLESHOOTING**

15

16 **Informatics for signal comparison • TIMING 8-9 h (for a 2-brain dataset, reduced**  
17 **to 1-2h if using affine registration instead of Symmetric Normalization)**

1 **▲CRITICAL** We provide our source code and an additional user manual as  
2 **Supplementary Data**, as well as NIfTI-1-converted Allen Brain Atlas data and  
3 Arc-dVenus Tg mouse brain images used in **Fig. 6** on our website (<http://cubic.riken.jp>).  
4 Note that timing is roughly proportional to the number of brains and vary on different  
5 computer specifications.

6

7 **7|** If this is the first time the pipeline is being run, install all required software and copy  
8 the provided code to the computer used for the analysis. Compile the C++ files for edge  
9 detection (`g++ -O3 edge_detection_Prewitt.cpp -o edge_detection_Prewitt`) and file  
10 merging (`g++ -O3 file_merging.cpp -o file_merging`).

11

12 **8|** Construct a 3D NIfTI-1 file for each TIFF stack with the *convertTiffFiles.py* script. This  
13 takes approximately 2 min per stack, and each brain sample corresponds to four stacks  
14 (two channels, two acquisition directions).

## 15 **? TROUBLESHOOTING**

16

17 **9|** Align images of the same brain acquired from opposite directions, with the  
18 *sameBrainAlignment.py* script. For each brain, this includes: registration of the

1 V-D-acquired nuclear counterstaining image to the D-V-acquired one, alignment of the  
2 V-D-acquired nuclear counterstaining image, alignment of the V-D-acquired signal  
3 channel image. The registration takes approximately 1 h 30 min using Symmetric  
4 Normalization or 3-5 min using affine transformations only, and both alignments take  
5 under a minute.

## 6 ? TROUBLESHOOTING

7

8 **10|** Merge the V-D-acquired and D-V-acquired images. Use *edgeDetection.py* to  
9 calculate the  $n$  and  $m$  thresholds for each brain and channel (4 min per brain), and use  
10 these results in *fileMerging.py* to merge the files (7-8 min per brain).

## 11 ? TROUBLESHOOTING

12

13 **11|** Choose one brain to be used as internal reference, and align all the other brains to  
14 this reference with *internalAlignment.py* (for each brain, approximately 1 h 30 min for  
15 the registration if using Symmetric Normalization or 3-5 min if using affine  
16 transformation only, and under a minute for the alignment of both channels).

## 17 ? TROUBLESHOOTING

18

1 **12|** Using *atlasAlignment.py*, register the internal reference to the brain atlas  
2 (approximately 1 h 30 min) and align all brains to the atlas (approximately 1 min per  
3 brain).

4 **? TROUBLESHOOTING**

5

6 **13|** Calculate the normalization factors (7 min, plus 7 min per brain) with  
7 *median\_brainOnly.py*.

8 **? TROUBLESHOOTING**

9

10 **14|** Normalize and compare brains (e.g. for subtraction) with  
11 *normalisation\_comparison.py* (exact timing dependent on comparison, but typically  
12 10-60 min).

13 **? TROUBLESHOOTING**

14

15 **15|** Export TIFF stack for the resulting files with *exportTiffStack.py* (about four min per  
16 NIfTI-1 file).

17 **▲ CRITICAL STEP** Although registration with SyN transformation is effective, in some  
18 cases it may cause structural deformation or distortion. Users can choose whether to

1 use SyN or affine-only registration. We recommend checking the quality of final aligned  
2 data and, if necessary trying SyN or affine-only instead. In this manuscript, we show  
3 data aligned with SyN in **Fig.5** and with affine-only transformation in **Fig.6**, for  
4 illustrative purposes.

5 **? TROUBLESHOOTING**

6

## 1 TROUBLESHOOTING

2 See Table 3 for troubleshooting guidance

## 4 ANTICIPATED RESULTS

5 The CUBIC pipeline can be used for whole-organs or -body clearing. It is simple,  
6 efficient, and reproducible and thus can be applied to simultaneous multi-sample  
7 clearing in a single tube (**Fig. 2c**, inset) or a plastic container. The procedure can be  
8 performed using equipment usually used in a typical biology laboratory (**Fig. 2a-d**). By  
9 simple immersion of sample in reagent-1, clearing is obvious within several hours (**Fig.**  
10 **2e**) and such partially cleared samples are even applicable to deep region imaging with  
11 two-photon microscopy<sup>18</sup>. The CUBIC reagents also decolorize organs and the whole  
12 body by removing heme, which is also apparent just after CB-Perfusion (**Fig. 3a** and **b**),  
13 and this ability enables whole-body clearing within two weeks (**Fig. 3c** and **d**). We  
14 summarize the organs we have used CUBIC on in **Table 1**. Removal of the CUBIC  
15 reagents by PBS wash reverses the cleared state (**Fig. 2e**), but the tissue is clear again  
16 if re-immersed into CUBIC reagents.

17 **Fig. 4a-f** shows typical imaging results for the Thy1-YFP-H Tg mouse brain at  
18 1.6× zoom. Overall, soma and other subcellular structures such as neurites in the  
19 mouse brain can be captured providing they are sparsely labeled (**Fig. 4b, d, e,**  
20 **Supplementary Video 1**). Other organs were also subjected to rapid, multi-color 3D

1 imaging in the same platform (**Fig. 4g** and **h**). Of note, these data were collected for  
2 approximately 30-60 min for each direction/color.

3           According to the user's experimental purpose, high or low resolution images  
4 may be acquired. We use relatively low resolution because our primary purpose is to  
5 analyze cells within the context of a whole organ or body in a high-throughput manner.  
6 However subcellular structures can be observed in the cleared tissue (**Fig. 4b-f**)<sup>18</sup> and  
7 thus CUBIC permits more detailed observations with a higher zoom on the LSM, or by  
8 using higher NA objective lenses on other confocal and two-photon microscopes .

9           We implemented an image informatics method originally used in fMRI analysis  
10 to compare different brains. In this pipeline, the acquired dataset are preprocessed by  
11 merging D-V and V-D to make sure the resulting images are clear throughout the  
12 Z-stack (**Fig. 5**). Then signal subtraction between samples is calculated (**Fig. 6**). Here  
13 we show an example of Arc-dVenus Tg mouse brains with or without light stimuli<sup>18, 26</sup>  
14 (**Fig. 6a**). The raw images were preprocessed, aligned and normalized, and then  
15 subtraction of Venus signal was calculated to visualize light-responsive regions at the  
16 whole-brain scale (**Fig. 6b-d**). These calculations could be achieved by whole-organ  
17 counterstaining in the CUBIC clearing protocol. Note that the final resolution of images  
18 in this process is downscaled and it is more difficult to achieve 'single-cell resolution'

1 throughout the entire imaging field, due to the current software limitations. This will be  
2 addressed in future studies.

3 In summary, CUBIC provides a platform for comprehensive cell detection and  
4 analysis across whole organs and the body. Possible applications of CUBIC will be for  
5 whole-organ samples from multiple conditions or timepoints, detection of aberrant 3D  
6 morphological changes in diseased tissues or a scalable observation of  
7 tissue-to-subcellular structures in a single cleared organ. The method will therefore  
8 support organism-level systems biology and facilitate our understanding of complicated  
9 biological phenomena in multicellular organisms.

10



1 **FIGURE LEGENDS**

2 **Figure 1**

3 Overview of the CUBIC pipeline. CUBIC is composed of 3 major stages (clearing,  
4 imaging, and analysis). For efficient and reproducible clearing, we provide three  
5 protocols: 1) simple immersion (step **2A**) which takes ~11 d in the case of a whole brain  
6 from an adult mouse (but varied according to the experimental purpose and organs), 2)  
7 CB-perfusion protocol for the whole adult mouse (step **2C**), which takes ~14 d, 3) the  
8 CB-Perfusion and immersion hybrid protocol (step **2B**) in which dissected organs after  
9 CB-Perfusion can be continuously cleared according to the simple immersion protocol.  
10 Rapid 3D imaging can be performed with an LSM. The collected data is processed and  
11 analyzed, such as signal comparison between samples as described in this manuscript.  
12 Images of actual samples correspond to the samples in **Fig. 2** and **3**. All animal  
13 experiments here were approved by the Animal Care and Use Committee of the RIKEN  
14 Kobe Institute and The University of Tokyo, and all of the animals were cared in  
15 accordance with the Institutional Guidelines.

16

17 **Figure 2**

1 Procedure of the simple immersion protocol. **(a)** Preparation of reagent-2. This reagent  
2 contains a high concentration of urea (25 wt%) and sucrose (50 wt%) (upper panel).  
3 These can be completely dissolved by heat and stirring with a microwave and a hot  
4 stirrer (lower panel). **(b)** A vacuum desiccator for the degas steps. **(c)** An incubator with  
5 shaker (a hybridization incubator) that we use for the clearing procedure. Inset: 5 brain  
6 samples treated with reagent-1 in a single tube (day 5). **(d)** A table shaker used for PBS  
7 washing step at room temperature. **(e)** Appearance of a brain sample in each step. A  
8 brain from C57BL/6 male mouse (8-week-old) was used. Reagent-1-treated sample is  
9 temporally swollen but the size is recovered after immersion in reagent-2. Scale bar: 5  
10 mm. All animal experiments here were approved by the Animal Care and Use  
11 Committee of the RIKEN Kobe Institute and The University of Tokyo, and all of the  
12 animals were cared in accordance with the Institutional Guidelines.

13

### 14 **Figure 3**

15 Procedure of the CB-Perfusion protocol. **(a)** Surgical setup for CB-Perfusion. The  
16 transcardiac perfusion line is connected to 1) heparin-PBS for flushing the blood, 2) 4%  
17 PFA on ice with peristaltic pump for fixation, 3) PBS for flushing PFA, and 4) 1/2-diluted  
18 reagent-1 for accelerative clearing through the vascular system. **(b)** Dissected organs

1 just after CB-Perfusion. Organs such as the pancreas, spleen or kidney are  
2 macroscopically cleared and decolored at this point. The clearance of these organs is  
3 indicative of how well researchers succeed in CB-Perfusion. Scale bar: 5 mm. **(c)**  
4 Clearing performance of CB-Perfused dissected organs at day 1 in reagent-1 and at day  
5 10 in reagent-2. CB-Perfused organs with a successful procedure are significantly  
6 transparent after 1 d of reagent-1 treatment. Some of the organs such as pancreas are  
7 more transparent in reagent-1 rather than in reagent-2. Scale bar: 5 mm. **(d)** Clearing  
8 performance of a CB-Perfused whole body just after CB-Perfusion and after two weeks  
9 of reagent-1 treatment. Organs such as pancreas, submaxillary gland and spleen tend  
10 quickly become transparent by CB-Perfusion. Major abdominal organs except bones  
11 and gastrointestinal content become sufficiently transparent after two weeks of  
12 reagent-1 treatment. C57BL/6 male mice (8-week-old) were used in **(b)-(d)**. All animal  
13 experiments here were approved by the Animal Care and Use Committee of the RIKEN  
14 Kobe Institute and The University of Tokyo, and all of the animals were cared in  
15 accordance with the Institutional Guidelines.

16

17 **Figure 4**

1 Whole-organ imaging with LSFM. **(a)** The microscope setup and the customized sample  
2 holder (inset) used in this manuscript. **(b)** Left: a raw TIFF image (2560 × 2160) from a  
3 cleared Thy1-YFP-H Tg mouse brain<sup>34</sup> (male, 23-week-old) (imaging conditions: Z = 10  
4 μm step × 749 planes, zoom = 1.6×, expose = 50 ms × two illuminations from each side,  
5 total acquisition time = about 30 min). The sample was cleared according to the  
6 immersion protocol in this manuscript. Right: a magnified image of the indicated area in  
7 the left panel. These images were minimally processed (sharpness, brightness and  
8 contrast) with ImageJ. **(c)** The reconstituted 3D image of the acquired data in **b**. A View  
9 from dorsal side is shown. **(d)** A magnified image of the indicated area in **c**. **(e)** A  
10 magnified image of the right hippocampus, viewed from the midline to lateral, as  
11 indicated in **c**. **(f)** A magnified image of the reconstituted X-Z image of the right  
12 hippocampus, as indicated in **c**. **(g)** The reconstituted 3D whole-organ images from  
13 β-actin-nuc-3×mKate2 KI mouse<sup>19</sup> (male, 8-week-old) (imaging condition: Z = 20 μm  
14 step × 350-500 planes, zoom = 0.8×-1.6×, expose = 100 ms to 2 s × two illuminations  
15 from each side, total acquisition time = about 45 min). The samples were cleared and  
16 stained with SYTO 16 according to the CB-Perfusion protocol. The magnified images of  
17 SYTO 16, mKate2, and merged signals at the approximate 1 mm depth of each organ  
18 (zoom = 5×). **(h)** The reconstituted 3D whole-organ images from a CAG-EGFP Tg<sup>35</sup>

1 stained with PI (male, 8-week-old) (imaging condition: Z = 20  $\mu$ m step  $\times$  350-500 planes,  
2 zoom = 0.8 $\times$ -1.6 $\times$ , expose = 100 ms to 2 s  $\times$  two illuminations from each side, total  
3 acquisition time = about 45 min). The samples were cleared and stained with PI  
4 according to the CB-Perfusion protocol. Brightness/contrast and minimal gamma-value  
5 of images in **c-h** were adjusted with Imaris. All animal experiments here were approved  
6 by the Animal Care and Use Committee of the RIKEN Kobe Institute and The University  
7 of Tokyo, and all of the animals were cared in accordance with the Institutional  
8 Guidelines.

9

## 10 **Figure 5**

11 Preprocessing of acquired 3D image for comparison analysis. Here we use the dataset  
12 of the Thy1-YFP-H Tg mouse brain acquired in ref. 18 as an example. “Collect raw  
13 images” panel shows the scheme of brain 3D imaging of two different directions (D-V  
14 and V-D). Raw TIFF images (here only YFP channel shown) in the panel are Z = 2.25  
15 mm (sharp) and 5.5 mm (blurred) for upper and lower panels, respectively. The raw  
16 dataset are downscaled to 25% and converted to NIFTI-1 files (shown as capture  
17 images of ITK-SNAP). Then, structural D-V data (shown as reconstituted 3D images)  
18 via nuclei counterstaining are registered to the corresponding V-D data. This step is to

1 calculate transformation parameters, which is applied to the signal D-V data in the  
2 following step (alignment). We then merge the aligned images in order to ensure  
3 sharpness throughout the resulting 3D image (YFP channel is shown as an example  
4 again). To do so, the “edge content” based on the Prewitt operator is calculated for both  
5 D-V and V-D images. This is used to define two threshold values at Z slice position  $n$   
6 and  $m$  and to create the merged composite NIfTI-1 image (shown as capture images of  
7 ITK-SNAP) according to these values.

8 The reconstituted 3D images and plane images in the “Align” and “Combine” panels  
9 were prepared by using exported TIFF images from the corresponding NIfTI-1 data. 3D  
10 reconstitutions were performed with Imaris software as in **Fig. 4**, and shown as views  
11 from dorsal and ventral side in D-V and V-D images, respectively. All animal  
12 experiments here were approved by the Animal Care and Use Committee of the RIKEN  
13 Kobe Institute and The University of Tokyo, and all of the animals were cared in  
14 accordance with the Institutional Guidelines.

15

## 16 **Figure 6**

17 Calculation of signal subtraction. **(a)** Here we use the dataset of the Arc-dVenus Tg  
18 mouse brains with or without light stimuli, acquired in ref. 18 as an example ( $Z = 10 \mu\text{m}$

1 step × 625~675 planes, zoom = 2×, expose = 3 s × two illuminations for Venus and 300  
2 ms × two illuminations for PI, respectively). The reconstituted 3D images from raw TIFF  
3 stacks are shown as views from dorsal and ventral sides in D-V and V-D images,  
4 respectively. Yellow, Venus. Blue, PI. **(b)** We first preprocess these datasets as in **Fig. 5**.  
5 Then, we align one dataset, Light (+), to the other, Light (-), by registering the first  
6 structural data to the second (internal reference). The internal reference is also  
7 registered to a brain atlas such as the Allen Brain Atlas. All images are then aligned to  
8 the atlas and normalized. The 3D reconstituted images from NIfTI-1 data for structure  
9 and signal of Light (+) or (-) samples, after alignment to the internal reference (step 1 in  
10 the panel), are shown as dorsal side view. **(c)** Reconstituted 3D images of aligned and  
11 normalized Venus channel (yellow) and aligned PI channel (blue) images from the  
12 corresponding NIfTI-1 data. Views from dorsal side are shown. **(d)** Results of subtraction,  
13 shown as 3D reconstituted images. Views from dorsal side (left and upper right) and  
14 dorsolateral side (lower right) are shown. Signals observed in Light (+) or (-) conditions  
15 are shown in magenta and right blue, respectively. Standardized PI signals of Light (+)  
16 sample are merged and indicated in blue. As seen in the magnified panel (upper right),  
17 single cells in the sparsely labeled regions can be detected even in the downscaled  
18 images.

1 The reconstituted 3D images in **(b)-(d)** were prepared by using exported TIFF images  
2 from the corresponding NIfTI-1 data and with Imaris software as in **Fig. 4** and **5**. All  
3 animal experiments here were approved by the Animal Care and Use Committee of the  
4 RIKEN Kobe Institute, the Gifu University and The University of Tokyo, and all of the  
5 animals were cared in accordance with the Institutional Guidelines.  
6



**TABLE 1** | Tissues CUBIC has been successfully applied to.

| <b>Tissue</b>                                     | <b>Clearing protocol</b>           | <b>Reagent before imaging</b> | <b>Clearing efficiency</b>   |
|---|------------------------------------|-------------------------------|--|
| Mouse whole body* <sup>19</sup>                   | CB-Perfusion                       | Reagent-1 <sup>††</sup>       | Good   |
| Mouse brain <sup>18, 19</sup>                     | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Marmoset hemisphere** <sup>18</sup>               | Simple immersion                   | Reagent-2                     | Good   |
| Mouse heart <sup>19</sup>                         | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse lung <sup>19</sup>                          | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse spleen <sup>19</sup>                        | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse liver <sup>19</sup>                         | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse stomach <sup>19</sup>                       | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse intestine <sup>19</sup>                     | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse kidney <sup>19</sup>                        | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse pancreas <sup>19</sup>                      | Simple immersion<br>/ CB-Perfusion | Reagent-2 or<br>Reagent-1     | Good   |
| Mouse lymph node <sup>†</sup>                     | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse muscle <sup>19</sup>                        | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse skin*** <sup>19</sup>                       | Simple immersion<br>/ CB-Perfusion | Reagent-2                     | Good   |
| Mouse bone <sup>19</sup>                          | CB-Perfusion                       | Reagent-1                     | Partially cleared<br>but need further<br>investigations <sup>†††</sup> |
| Tissues with melanin (eye and hair) <sup>19</sup> | CB-Perfusion                       | -                             | Not cleared with<br>the current  |

\*We performed imaging of postnatal day-1 samples<sup>19</sup>. Imaging of cleared adult mouse was not tested due to size limitation of current LSFM setup.

\*\*So far we tested a brain sample of postnatal day-3. Adult brain will be tested in future studies.

\*\*\*Need hair removal

†Unpublished result

††The cleared body specimen can be stocked in the reagent.

†††Bone clearing of infant mice was sufficient for imaging<sup>19</sup>

**TABLE 2** | Other clearing methods and their applications to imaging and analysis

| <b>Methods</b>                   | <b>Chemical contents</b>  | <b>Applied imaging methods</b>  | <b>Applied computational analysis methods</b>  |
|----------------------------------|---|---|--|
| CUBIC <sup>18, 19</sup>          | Quadrol /<br>Triethanolamine /<br>Triton X-100 /<br>Urea / Sucrose  | Ultramicroscope<br>(LSFM),<br>Two-photon<br>microscopy,<br>Confocal<br>microscopy | Whole-brain signal<br>comparison analysis,<br>Extraction of anatomical and<br>histological structures,<br>Quantitative analysis of<br>pancreatic Langerhans islets |
| 3DISCO <sup>4, 5, 7, 36-38</sup> | Ethanol or<br>Methanol /<br>Xylene / Benzyl<br>alcohol / Benzyl<br>benzoate for<br>BABB method<br><br>Tetrahydrofuran /<br>Dichloromethane<br>/ Dibenzyl ether<br>for THF-DBE<br>method | Ultramicroscope<br>(LSFM),<br>Two-photon<br>microscopy,<br>Confocal<br>microscopy | 3D reconstruction,<br>Visualization of intensities,<br>Axon tracing, Cell number<br>quantification, Tumor volume<br>calculation                                    |
| Scale <sup>9</sup>               | Urea / glycerol /<br>Triton X-100   | Two-photon<br>microscopy,<br>Confocal<br>microscopy                               | 3D reconstruction, Distance<br>measurement   |
| SeeDB <sup>10</sup>              | D(-)-Fructose /<br>$\alpha$ -thioglycerol   | Two-photon<br>microscopy,<br>Confocal<br>microscopy                               | 3D reconstruction, Axon and<br>dendrite tracing, Cell<br>distribution analysis   |

|   |  |   |                                    |
|---|--|---|------------------------------------|
| FRUIT <sup>14</sup>                               | D(-)-Fructose / urea   | Two-photon microscopy   |                                    |
| <i>Clear</i> <sup>T11</sup>                       | Formamide for <i>Clear</i> <sup>T</sup> , Formamide and polyethylene glycol for <i>Clear</i> <sup>T2</sup>   | Optical Sectioning Microscopy, Stereomicroscopy                                     |                                    |
| 2,2'-Thiodiethanol <sup>1</sup><br>2, 13          | 2,2'-Thiodiethanol   | Two-photon microscopy, Confocal microscopy, Two-photon serial sectioning tomography | 3D reconstruction                  |
| CLARITY and related methods <sup>*13, 15-17</sup> | SDS in borate buffer / one of FocusClear <sup>TM</sup> , RIMS (Histodenz or Sorbitol), or 2,2'-Thiodiethanol | Confocal microscopy, Two-photon microscopy, COLM and other custom LSFM              | 3D reconstruction, Neurite tracing |

\*Use acrylamide-embedded specimen

**TABLE 3** | Troubleshooting table.

| Step                        | Problem   | Possible reason                                | Possible solution  |
|-----------------------------|---|--|--|
| Preparation (REAGENT SETUP) | Possible degradation of chemicals in CUBIC reagents | Too much heating (which causes ammonia odor)   | Milder and shorter heating during preparation                                  |
|                             | Precipitate in reagent-2                            | Lower room temperature, particularly in winter | Prepare the reagent before use; heat with microwave for 5-10 s (avoid boiling) |

|   |                                      |  |   |
|---|--------------------------------------|--|---|
| Fixation<br>(Steps 2A(i) and 2B(iii))                 | Poor PFA perfusion                   | Insufficient cooling of PBS and PFA                    | Keep PBS and PFA on ice just before perfusion   |
|   |                                      | Wrong position of the tip of needle                    | Make sure that the tip of needle is in the left ventricle of the heart  |
|   |                                      | Insufficient pressure for perfusion                    | Make sure perfusion outlet only occurs at the cut in the liver  |
| Clearing<br>(Steps 2A(iv-viii), 2B(v-ix) and 2C(iii)) | Poor organ clearing during reagent-1 | Alkaline pH of PFA                                     | Adjust pH of PFA to approximately 7.4   |
|   |                                      | Too much fixation time                                 | Stop post-fixation within 24 h  |
|   |                                      | Insufficient incubation time, reagent amount or mixing | Incubate longer in reagent-1 (a few days more); Exchange reagent-1 more frequently (every day rather than every 2 d); Shake or rotate appropriately |
|   |                                      | Use of an aged animal                                  | Use a younger animal  |
|   |                                      | Organ-dependent differences in clearing                | Use reagent-1 rather than reagent-2 for the final clearing reagent (e.g. pancreas becomes clearer in the reagent-1, see <b>Fig. 3</b> )             |

|  |  |  |
|--|--|--|
| Excess shrinkage or deformation of cleared organ after reagent-2 | Inappropriate concentration of salt whilst treating with 1/2 reagent-2 | If shrunk too much, decrease the concentration of PBS in the 1/2 reagent-2 (e.g. mix 1:1:2 of distilled water:PBS:reagent-2 rather than 1:1 mix of PBS:reagent-2); usage of 1/2 reagent-2/water instead of PBS causes swelling |
|  | Incubation at 37°C   | Try to incubate samples at room temperature during reagent-2 steps (takes more time)   |
|  | Insufficient replacement in 1/2 reagent-2                              | Sufficiently incubate in the reagent for complete replacement  |
|  | Use of an infant/juvenile animal                                       | Organs from an infant/juvenile animal tend to shrink more in reagent-2 and need less incubation time during reagent-1 treatment  |
|  | Use of samples prepared in CB-Perfusion                                | Try simple immersion protocol  |
| Poor organ clearing during reagent-2                             | Incomplete dissolution or precipitate in reagent-2                     | Make sure no precipitate exists in the prepared/stocked reagent-2  |
|  | Insufficient incubation in reagent-1                                   | Increase reagent-1 treatment time  |

|                  |  |  |   |
|------------------|--|--|---|
|                  |  | Insufficient replacement into reagent-2  | Make sure to incubate at 37°C during reagent-2; Use more volume of reagent-2 and exchange the reagent one or two more times |
|                  | Ammonia smell during clearing  | Degradation of urea  | Change the fresh media, and avoid too much heating during preparation of reagents   |
|                  | Bubbles on inside structures of organs (e.g. brain ventricles) after reagent-2 | Insufficient degas   | Degas the reagent-2 after preparation; Degas the sample in a limited volume of PBS before the reagent-2 incubation          |
|                  |  | Rotation during reagent-2  | Incubate in the reagent-2 with gentle shaking rather than rotation  |
|                  | Tissue damage on freezing  | Keeping the sample at -20°C ~ -30°C (which possibly causes growth of water crystals inside the tissue) | Stock the sample in O.C.T. compound at -80°C; Thaw the sample gradually at room temperature                                 |
|                  |  | Insufficient replacement by sucrose solution   | Increase incubation time in the sucrose solution (i.e. until organs sink)   |
| Imaging (Step 6) | Floating sample during imaging   | Usage of reagent-2 rather  | Immerse the sample in oil   |

than the immersion  
oil mix

|                                     |                                       |   |
|-------------------------------------|---------------------------------------|---|
| Bubble on the surface               | Insufficient removal of the reagent-2 | Remove excess reagent-2 before immersion into the oil mix; Remove bubbles in the oil with a needle or a tapered forceps   |
| High auto-fluorescence              | Insufficient fluorescent signal       | Select a bright fluorescent protein (e.g. YFP, Venus) with a strong expression promoter (e.g. CAG); Avoid green channel and use a red fluorescent protein (e.g. mKate2)                                     |
|                                     | Alkaline pH of PFA                    | Adjust pH of PFA to approximately 7.4   |
|                                     | Use of an aged animal                 | Use a younger animal  |
| Weak or non-detectable fluorescence | Insufficient fluorescent signals      | Select a bright fluorescent protein with a strong expression promoter as above  |
|                                     | Signal decrease in CB-Perfusion       | Use more PFA for perfusion and pause the perfusion procedure after PFA perfusion to increase fixation reaction (3 h~); Try the immersion protocol; Select an animal strain with a bright fluorescent signal |

|                       |   |  |  |
|-----------------------|---|--|--|
|                       |   | Temperature during clearing                | Higher temperature during clearing may decrease fluorescence signals <sup>8</sup> . Try to incubate at room temperature rather than 37°C. (Note that lower temperature also decreases clearing efficiency)   |
|                       |   | Inappropriate setting of microscopy        | Check the setting of laser power, filter and exposure time   |
|                       | Poor Z resolution                                   | Inappropriate setting of light-sheet focus | Adjust the light-sheet focus to the region of interest (in the case of LaVision Ultramicroscope, the width of focused sheet is 1/3-1/4 of an adult mouse hemisphere and thus it is impossible to take images with adjusted focus throughout the brain) |
| Analysis (Steps 8-15) | Brain appears deformed in the NIfTI-1 file (Step 8) | Wrong scaling                              | Check the parameter file and ensure that the correct voxel dimensions are given (for the raw TIFF image, in mm)  |
|                       | Incorrect brain orientation (Step 8)                | Different brain position during imaging    | Reorient the NIfTI-1 file in ITK-SNAP until it matches your raw TIFF stack. Note the correct orientation (e.g. RPS) and edit the convertTiffFiles.py script accordingly (line 148 for DV-acquired files, line 150 for VD-acquired ones)                |



|  |   |   |
|--|---|---|
| Error message:<br>"No such file or<br>directory" | Wrong folder name<br>or brain ID in the<br>parameter file | Check the parameter file for<br>that step and ensure that all<br>brain IDs are valid and that all<br>folders exist  |
| Error message:<br>"Command not<br>found"         | Missing software  | Make sure that all the required<br>tools are installed, that they are<br>accessible from the command<br>line, and that our two C++<br>programs are compiled |

---

1

2

1 **COMPETING FINANCIAL INTERESTS**

2 The authors declare competing financial interests (see the HTML version of this article  
3 for details).

4

## 1 **ACKNOWLEDGMENTS**

2 We thank the lab members at RIKEN QBiC, and The University of Tokyo in particular,  
3 S.I.Kubota for his kind help in preparing the materials; A. Millius for his critical reading  
4 and editing of the manuscript; T Mano for his kind contributions and suggestions to  
5 discuss image resolution. This work was supported by the Program for Innovative Cell  
6 Biology by Innovative Technology and the Brain Mapping by Integrated  
7 Neurotechnologies for Disease Studies (Brain/MINDS) from the Ministry of Education,  
8 Culture, Sports, Science and Technology (MEXT) of Japan, a Grant-in-Aid for Scientific  
9 Research (S) (Grant No. 25221004), a Grant-in-Aid for Scientific Research on  
10 Innovative Areas (Grant No. 23115006), a Grant-in-Aid for Young Scientists (A) (Grant  
11 No. 15H05650) from MEXT/Japan Society for the Promotion of Science (JSPS), the  
12 strategic programs for R&D (President's discretionary fund) of RIKEN, an intramural  
13 Grant-in-Aid from the RIKEN Quantitative Biology Center, a grant from Core Research  
14 for Evolutional Science and Technology (CREST) Japan Science and Technology  
15 Agency (JST), the RIKEN Special Postdoctoral Research Program, the RIKEN Foreign  
16 Postdoctoral Researcher Program, a Grant-in-Aid from Japan Foundation for Applied  
17 Enzymology, from the Brain Sciences Project of the Center for Novel Science Initiatives  
18 of National Institutes of Natural Sciences (Grant No. BS261004), from the Tokyo Society

1 of Medical Science, from the Shimabara Science Promotion Foundation.

2

1 **Author Contributions Statement**

2 H.R.U., E.A.S., K.T., and D.P. designed the study. E.A.S., H.Y., and A.K. performed  
3 most of the immersion protocol. K.T. performed most of the CB-Perfusion protocol. D.P.  
4 performed most of the computational image analysis. A.K. developed the improved  
5 immersion protocol. All authors discussed the results and commented on the  
6 manuscript text.

1 **SUPPLEMENTARY INFORMATION**

2 **Supplementary Video 1**

3 Spot-counting analysis of hippocampal neurons in Thy1-YFP-H Tg mouse brain shown  
4 in **Fig. 4b-f**. Almost all cells are roughly detected as single spots in such a relatively  
5 dense region. The analysis was performed with Imaris software. Some of parameters  
6 are manually adjusted.

7

## 1 REFERENCE

- 2 1. Keller, P.J. & Ahrens, M.B. Visualizing whole-brain activity and development at the  
3 single-cell level using light-sheet microscopy. *Neuron* **85**, 462-483 (2015).
- 4 2. Osten, P. & Margrie, T.W. Mapping brain circuitry with a light microscope. *Nat.*  
5 *Methods* **10**, 515-523 (2013).
- 6 3. Spalteholz, W. *Über das Durchsichtigmachen von menschlichen und tierischen*  
7 *Präparaten.* (S. Hirzel, Leipzig; 1914).
- 8 4. Dodt, H.U. et al. Ultramicroscopy: Three-dimensional visualization of neuronal  
9 networks in the whole mouse brain. *Nat. Methods* **4**, 331–336 (2007).
- 10 5. Ertürk, A. et al. Three-dimensional imaging of solvent-cleared organs using 3DISCO.  
11 *Nat. Protoc.* **7**, 1983–1995 (2012).
- 12 6. Becker, K., Jährling, N., Saghafi, S., Weiler, R. & Dodt, H.U. Chemical clearing and  
13 dehydration of GFP expressing mouse brains. *PLoS ONE* **7**, e33916 (2012).
- 14 7. Renier, N. et al. iDISCO: a simple, rapid method to immunolabel large tissue  
15 samples for volume imaging. *Cell* **159**, 896-910 (2014).
- 16 8. Schwarz, M.K. et al. Fluorescent-protein stabilization and high-resolution imaging of  
17 cleared, intact mouse brains. *PLoS ONE* **10**, e0124650 (2015).
- 18 9. Hama, H. et al. *Scale*: a chemical approach for fluorescence imaging and

- 1 reconstruction of transparent mouse brain. *Nat. Neurosci.* **14**, 1481–1488 (2011).
- 2 10. Ke, M.T., Fujimoto, S. & Imai, T. SeeDB: a simple and morphology-preserving  
3 optical clearing agent for neuronal circuit reconstruction. *Nat. Neurosci.* **16**, 1154–  
4 1161 (2013).
- 5 11. Kuwajima, T. et al. *Clear<sup>T</sup>*: a detergent- and solvent-free clearing method for  
6 neuronal and non-neuronal tissue. *Development* **140**, 1364-1368 (2013).
- 7 12. Aoyagi, Y., Kawakami, R., Osanai, H., Hibi, T. & Nemoto, T. A rapid optical clearing  
8 protocol using 2,2'-thiodiethanol for microscopic observation of fixed mouse brain.  
9 *PLoS ONE* **10**, e0116280 (2015).
- 10 13. Costantini, I. et al. A versatile clearing agent for multi-modal brain imaging. *Sci. Rep.*  
11 **5**, 9808 (2015).
- 12 14. Hou, B. et al. Scalable and Dil-compatible optical clearance of the mammalian brain.  
13 *Front. Neuroanat.* **9**, 19 (2015).
- 14 15. Chung, K. et al. Structural and molecular interrogation of intact biological systems.  
15 *Nature* **497**, 332–337 (2013).
- 16 16. Tomer, R., Ye, L., Hsueh, B. & Deisseroth, K. Advanced CLARITY for rapid and  
17 high-resolution imaging of intact tissues. *Nat. Protoc.* **9**, 1682-1697 (2014).
- 18 17. Yang, B. et al. Single-cell phenotyping within transparent intact tissue through



- 1 whole-body clearing. *Cell* **158**, 945-958 (2014).
- 2 18. Susaki, E.A. et al. Whole-brain imaging with single-cell resolution using chemical  
3 cocktails and computational analysis. *Cell* **157**, 726-739 (2014).
- 4 19. Tainaka, K. et al. Whole-body imaging with single-cell resolution by tissue  
5 decolorization. *Cell* **159**, 911-924 (2014).
- 6 20. Keller, P.J., Schmidt, A.D., Wittbrodt, J. & Stelzer, E.H.K. Reconstruction of  
7 zebrafish early embryonic development by scanned light sheet microscopy. *Science*  
8 **322**, 1065–1069 (2008).
- 9 21. Keller, P.J. et al. Fast, high-contrast imaging of animal development with scanned  
10 light sheet-based structured-illumination microscopy. *Nat. Methods* **7**, 637–642  
11 (2010).
- 12 22. Ahrens, M.B., Orger, M.B., Robson, D.N., Li, J.M. & Keller, P.J. Whole-brain  
13 functional imaging at cellular resolution using light-sheet microscopy. *Nat. Methods*  
14 **10**, 413-420 (2013).
- 15 23. Panier, T. et al. Fast functional imaging of multiple brain regions in intact zebrafish  
16 larvae using selective plane illumination microscopy. *Front. Neural Circuits* **7**, 65  
17 (2013).
- 18 24. Murphy, K. et al. Evaluation of registration methods on thoracic CT: the EMPIRE10

- 1 challenge. *IEEE Trans. Med. Imaging* **30**, 1901–1920 (2011).
- 2 25. Yushkevich, P.A. et al. User-guided 3D active contour segmentation of anatomical  
3 structures: Significantly improved efficiency and reliability. *Neuroimage* **31**, 1116–  
4 1128 (2006).
- 5 26. Eguchi, M. & Yamaguchi, S. *In vivo* and *in vitro* visualization of gene expression  
6 dynamics over extensive areas of the brain. *Neuroimage* **44**, 1274–1283 (2009).
- 7 27. Prewitt, J.M.S. Object Enhancement and Extraction In *Picture Processing and*  
8 *Psychopictorics* (eds. Lipkin, B.S. & Rosenfeld, A.) 75-149 (Academic Press, New  
9 York, USA, 1970).
- 10 28. Jenkinson, M., Beckmann, C.F., Behrens, T.E., Woolrich, M.W. & Smith, S.M. Fsl.  
11 *Neuroimage* **62**, 782–790 (2012).
- 12 29. Lein, E.S. et al. Genome-wide atlas of gene expression in the adult mouse brain.  
13 *Nature* **445**, 168-176 (2007).
- 14 30. Alnuami, A.A., Zeedi, B., Qadri, S.M. & Ashraf, S.S. Oxyradical-induced GFP  
15 damage and loss of fluorescence. *Int. J. Biol. Macromol.* **43**, 182-186 (2008).
- 16 31. Steinke, H. & Wolff, W. A modified Spalteholz technique with preservation of the  
17 histology. *Ann. Anat.* **183**, 91-95 (2001).
- 18 32. Faisal, A.A., White, J.A. & Laughlin, S.B. Ion-channel noise places limits on the

- 1       miniaturization of the brain's wiring. *Curr. Biol.* **15**, 1143-1149 (2005).
- 2       33. Richards, K.L. et al. Hippocampal volume and cell density changes in a mouse  
3       model of human genetic epilepsy. *Neurology* **80**, 1240-1246 (2013).
- 4       34. Feng, G.P. et al. Imaging neuronal subsets in transgenic mice expressing multiple  
5       spectral variants of GFP. *Neuron* **28**, 41–51 (2000).
- 6       35. Okabe, M., Ikawa, M., Kominami, K., Nakanishi, T. & Nishimune, Y. 'Green mice' as  
7       a source of ubiquitous green cells. *FEBS Lett.* **407**, 313-319 (1997).
- 8       36. Ertürk, A. et al. Three-dimensional imaging of the unsectioned adult spinal cord to  
9       assess axon regeneration and glial responses after injury. *Nat. Med.* **18**, 166-171  
10      (2012).
- 11      37. Soderblom, C. et al. 3D Imaging of Axons in Transparent Spinal Cords from Rodents  
12      and Nonhuman Primates. *eNeuro* **2** (2015).
- 13      38. Weber, T.G. et al. Apoptosis imaging for monitoring DR5 antibody accumulation and  
14      pharmacodynamics in brain tumors noninvasively. *Cancer Res.* **74**, 1913-1923  
15      (2014).
- 16
- 17